<SEC-DOCUMENT>0001104659-26-084619.txt : 20260717
<SEC-HEADER>0001104659-26-084619.hdr.sgml : 20260717
<ACCEPTANCE-DATETIME>20260717160525
ACCESSION NUMBER:		0001104659-26-084619
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20260717
DATE AS OF CHANGE:		20260717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tvardi Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001346830
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295496
		FILM NUMBER:		261183762

	BUSINESS ADDRESS:	
		STREET 1:		3 SUGAR CREEK CTR. BLVD.
		STREET 2:		STE 525
		CITY:			SUGAR LAND
		STATE:			TX
		ZIP:			77478
		BUSINESS PHONE:		(713) 489-8654

	MAIL ADDRESS:	
		STREET 1:		3 SUGAR CREEK CTR. BLVD.
		STREET 2:		STE 525
		CITY:			SUGAR LAND
		STATE:			TX
		ZIP:			77478

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cara Therapeutics, Inc.
		DATE OF NAME CHANGE:	20100721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cara Therapeutics Inc
		DATE OF NAME CHANGE:	20051213
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2620412-1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title>tm2620412-1_424b5 - none - 6.218802s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Filed Pursuant to Rule&#160;424(b)(5)</font>&#8203;</div>
        <div style="text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-295496</font>&#8203;</div>
        <div style="margin-top:-0.2pt; width:541.31pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT </font> <br ><font style="letter-spacing:-0.2pt;">(To Prospectus dated May&#160;12, 2026)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:541.31pt;">
          <img src="lg_tvardi-4c.jpg" alt="[MISSING IMAGE: lg_tvardi-4c.jpg]" height="54" width="135" >
        </div>
        <div style="margin-top:16.6pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $9,689,765</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:11.167pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:11.81pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We previously entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC (&#8220;Jones&#8221;), relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, pursuant to this prospectus supplement and the accompanying prospectus, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to $9,689,765. We previously filed a prospectus dated May&#160;12, 2026, relating to the offer and sale of our common stock under the Sales Agreement having an aggregate offering price of up to $12,500,000. No additional common stock will be sold under the previously filed prospectus following the date of this prospectus supplement. We sold an aggregate of 3,110,769 shares of common stock for an aggregate offering price of approximately $11.0 million in gross proceeds under the previously filed prospectus (the &#8220;Prior Sales&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TVRD.&#8221; On July 16, 2026, the last reported sale price of our common stock as reported on Nasdaq was $3.08 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Jones is not required to sell any specific number or dollar amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Jones and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. See &#8220;Plan of Distribution&#8221; beginning on page S-13 for additional information regarding the compensation to be paid to Jones. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Jones will be entitled to a commission of up to 3.0% of the aggregate gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of our common stock on our behalf, Jones will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Jones will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contributions to Jones against certain civil liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the Registration Statement of which this prospectus supplement forms a part. The aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $62,208,945, which was calculated based on 12,441,789 shares of our outstanding common stock held by non-affiliates on July 16, 2026, at a price of $5.00 per share, the closing price of our common stock on July 8, 2026. During the prior twelve-calendar month period that ends on and includes the date of this prospectus supplement, we have sold approximately $11.0 million of common stock pursuant to General Instruction I.B.6. </font>
        </div>
        <div style="margin-top:18.4pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:11.9pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">S-7</a> of this prospectus supplement as well as those contained in any related free writing prospectus we prepare or authorize in connection with this offering, and under similar headings in the documents that are incorporated by reference into this prospectus supplement concerning factors you should consider before investing in our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the disclosures in this prospectus supplement. Any representation to the contrary is a criminal offense. </font>
        </div>
        <div style="margin-top:18.4pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 40.024%; margin-right: 40.024%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:15.9pt; text-align:center; width:541.31pt; line-height:20pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Jones</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus supplement is July 17, 2026.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:177pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus Supplement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:160pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">S-1</a></font><a href="#tATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU">S-2</a></font><a href="#tPRSU"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">S-7</a></font><a href="#tRIFA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">S-9</a></font><a href="#tSNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">S-11</a></font><a href="#tUOP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">S-12</a></font><a href="#tDIL"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">S-14</a></font><a href="#tPOD"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">S-16</a></font><a href="#tLEMA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">S-16</a></font><a href="#tEXP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">S-16</a></font><a href="#tWYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">S-17</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:205pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sATP">ii</a></font><a href="#sATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSUM"><font style="letter-spacing:0.2pt;">SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSUM">1</a></font><a href="#sSUM"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sRIFA">6</a></font><a href="#sRIFA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSNRF">7</a></font><a href="#sSNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sUOP">9</a></font><a href="#sUOP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDOCS">10</a></font><a href="#sDOCS"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDODS">15</a></font><a href="#sDODS"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDOW">22</a></font><a href="#sDOW"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLOOS"><font style="letter-spacing:0.2pt;">LEGAL OWNERSHIP OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLOOS">24</a></font><a href="#sLOOS"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPOD">27</a></font><a href="#sPOD"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLEMA">29</a></font><a href="#sLEMA"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sEXP">29</a></font><a href="#sEXP"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sWYCF">29</a></font><a href="#sWYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sIOCI">30</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus relates to an offering of our common stock. Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus. These documents contain important information that you should consider when making your investment decision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless the context requires otherwise, references in this prospectus to &#8220;Tvardi,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Tvardi Therapeutics, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes the terms of this offering of common stock and also adds to, updates and changes information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference that was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference into this prospectus&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not, and Jones has not, authorized anyone to provide you with information different from that which is contained in or incorporated by reference in this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. No one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus is accurate as of the date on the front cover of this prospectus only and that any information we have incorporated by reference is accurate only as of the date given in the document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time of delivery of this prospectus, any related free writing prospectus, or any sale of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained herein and under similar headings in the documents that are incorporated by reference into this prospectus. </font>
        </div>
        <div style="margin-left:20pt; margin-top:5pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, investors should not place undue reliance on this information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus, including the information incorporated by reference into this prospectus, include trademarks, service marks and trade names owned by us or others. All trademarks, service marks and trade names included or incorporated by reference in this prospectus or any related free writing prospectuses are the property of their respective owners.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights certain information about us and this offering and selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of the Company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference into this prospectus, and the information included in any free writing prospectus that we authorize for use in connection with this offering, including the information contained in and incorporated by reference under the heading &#8220;Risk Factors&#8221; beginning on page S-6 of this prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (&#8220;STAT3&#8221;) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders&#8217; seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase&#160;1b/2 clinical development in hepatocellular carcinoma (&#8220;HCC&#8221;). We expect to report topline data of TTI-101 across the three cohorts of the REVERT LIVER CANCER Phase&#160;1b/2 clinical trial in patients with HCC. TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance systemic drug delivery and improve tolerability. We submitted an Investigational New Drug (&#8220;IND&#8221;) application for TTI-109 in June&#160;2025 and, following FDA acceptance, initiated a Phase&#160;1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics and bioequivalence to TTI-101. We reported positive topline data from this trial in July&#160;2026. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;"> and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven immune cell populations across Th17, T follicular helper (&#8220;Tfh&#8221;) and B cell subsets. See &#8220;&#8212; Recent Developments.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In October&#160;2025, we reported preliminary data from our Phase&#160;2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) and concluded that the study did not meet its goals. Subsequently, we conducted additional analyses of a subset of patients who received study drug for 12 weeks. Based on these analyses, which excluded certain patients due to dosing, pharmacokinetic, or clinical factors, treatment with TTI-101 demonstrated greater reductions in certain exploratory measures, including fibrosis and inflammatory markers, compared to placebo&#8201;&#8212;&#8201;directly recapitulating findings from multiple preclinical models of fibrotic disease and providing human clinical proof of concept for the STAT3 inhibition mechanism. We continue to evaluate these results to inform potential future development decisions. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our approach is rooted in our expertise around STAT3&#8217;s functional composition and its critical role in disease pathogenesis, as well as other essential biological functions. Our co-founder, David J. Tweardy, M.D., was one of the first to identify that STAT3, when activated by phosphorylation on tyrosine (Y)&#160;residue 705 (pY-STAT3), acts as a central node across multiple inflammatory, proliferative and immune pathways. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Intrinsically (within proliferative cells), pY-STAT3 enhances cell proliferation and survival, while extrinsically (within the immune system), pY-STAT3 contributes to immune dysregulation. Collectively, persistent pY-STAT3 drives the development and progression of inflammatory and proliferative diseases characterized by dysregulated STAT3 signaling. By targeting pY-STAT3, our approach is designed to simultaneously modulate key pathways of the inflammatory and proliferative cascade, whereas previous approaches only targeted single pathways. Beyond its role in inflammation and proliferation, STAT3 also has an essential role in cellular respiration in the mitochondria. Dr.&#160;Tweardy made the critical discovery that blocking pY-STAT3 could inhibit STAT3&#8217;s role as a transcription factor without affecting its role in the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">mitochondria. We have leveraged this discovery to design our product candidates to inhibit STAT3 activation which, we believe, will lead to disease modifying activity without impairing essential biological functions. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We believe our oral small molecule STAT3 inhibitors have the potential for broad applicability across a diverse range of inflammatory and proliferative diseases driven by immune dysregulation, aberrant cytokine signaling, pathologic cellular proliferation, and maladaptive tissue remodeling. Across multiple preclinical models involving hematopoietic, gastrointestinal, dermatologic, respiratory organ specific tissue pathology, inhibition of STAT3 signaling has been associated with reductions in inflammatory burden, proliferation and improvement in disease relevant histological, molecular and clinical parameters. Importantly, clinical data from the REVERT IPF trial, including observed reductions in IL-6 and improvements in fibrosis score, is consistent with preclinical observations, which we believe supports the translational validity of our platform. </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Pipeline</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our current pipeline is depicted below: </font>
          </div>
          <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
            <img src="tb_pipeline2-4c.jpg" alt="[MISSING IMAGE: tb_pipeline2-4c.jpg]" height="196" width="555" >
          </div>
          <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The FDA has granted orphan drug designation for TTI-101 in both IPF and HCC as well as Fast-Track Designation for TTI-101 in HCC. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Recent Developments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Results from TTI-109 Phase&#160;1 Clinical Trial</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In July&#160;2026, we announced Phase&#160;1 results for TTI-109, our next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound&#8217;s mechanism of action. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;"> and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh and B cell subsets. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Key findings included: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Confirmed prodrug conversion and exposure equivalence: Validating its prodrug design, TTI-109 rapidly converted to TTI-101 within two hours and produced nearly identical plasma levels at molar-equivalent doses. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Sustained target-level exposure: 21-day repeat dosing showed stable, dose-proportional pharmacokinetics, with TTI-101 concentrations above the STAT3 IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50.</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Evidence of target engagement: Pharmacodynamic data showed reductions of up to 60% across disease-relevant STAT3-driven immune cell populations including Th17 cells, Tfh and B cell subsets. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Improved tolerability vs. TTI-101: Compared with placebo, diarrhea events with TTI-109 were similar in duration, transient and resolved without treatment interruption. Compared with TTI-101 at near-equivalent doses, diarrhea events with TTI-109 were substantially shorter in duration (0.46&#160;vs. 3.35&#160;days). </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have identified dermatologic and gastrointestinal therapeutic areas with shared STAT3-driven disease biology, specifically the convergence of cytokines, growth factors and Th17 and B cell immune pathways at the STAT3 node. TTI-109 is designed to address both the cellular and humoral components of inflammation and proliferation with a single oral agent. Recent programs in related STAT3-driven indications have validated the underlying biology, but each acts on a single upstream target, while TTI-109 targets STAT3, the downstream node where these pathways converge. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">STAT3 sits at the center of the core disease processes in dermatologic and gastrointestinal diseases, including inflammation, proliferation and cellular and humoral dysregulation. Our STAT3 inhibitors have demonstrated biologic activity in these pathways in both preclinical models and in the clinic. In preclinical disease models, our STAT3 inhibitors reduced inflammatory cascades, fibrosis and modulated immune activity. Similarly, in humans, TTI-101 reduced activated STAT3 levels, inflammatory cascades and fibrosis. The TTI-109 healthy volunteer study extended this translational profile, with reductions in STAT3-driven immune cell populations. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our ability to initiate these programs is subject to clearance of an Investigational New Drug application and the availability of additional funding. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were originally incorporated in Delaware in July&#160;2004 as Cara Therapeutics, Inc. (&#8220;Cara&#8221;). On April&#160;15, 2025 (the &#8220;Closing Date&#8221;), Cara, now known as Tvardi Therapeutics, Inc., completed its previously announced merger with the Delaware corporation formerly known as Tvardi Therapeutics, Inc. (&#8220;Legacy Tvardi&#8221;) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of December&#160;17, 2024 (the &#8220;Merger Agreement&#8221;), by and among Cara, CT Convergence Merger Sub, Inc., a wholly owned subsidiary of Cara (&#8220;Merger Sub&#8221;), and Legacy Tvardi, pursuant to which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the merger as a wholly owned subsidiary of Cara (the &#8220;Merger&#8221;). Also on April&#160;15, 2025, Cara changed its name from &#8220;Cara Therapeutics, Inc.&#8221; to &#8220;Tvardi Therapeutics, Inc.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, on the Closing Date, (i)&#160;Cara effected a 1-for-3 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;), (ii)&#160;Cara increased its authorized shares of common stock to 150,000,000, (iii)&#160;Merger Sub was merged with and into Legacy Tvardi and Legacy Tvardi became a wholly owned subsidiary of the Company, and (iv)&#160;the Company changed its name to &#8220;Tvardi Therapeutics, Inc.&#8221; As of the open of trading on April&#160;16, 2025, the common stock of the Company began trading on Nasdaq under the symbol &#8220;TVRD.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas&#160;77478, and our telephone number is (713) 489-8654. Our website address is www.tvarditherapeutics.com. Information contained on or accessible through our website is not a part of this prospectus, the accompanying base prospectus or any related free writing prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> or </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">TM</font><font style="letter-spacing:0.2pt;"> symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Smaller reporting companies may take advantage of certain reduced disclosure obligations. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation and other matters. We may continue to be a smaller reporting company in any given year if either (i)&#160;the market value of our stock </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">held by non-affiliates is less than $250&#160;million as measured on the last business day of our most recently completed second fiscal quarter, or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million as measured on the last business day of our most recently completed second fiscal quarter. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">As a result, the information that we provide to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Shares of our common stock having an aggregate offering price up to $9,689,765. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Common stock to be outstanding after this offering </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Up to 15,638,140 shares (as more fully described in the notes following this table), assuming sales of 3,146,027 shares of our common stock in this offering at an offering price of $3.08 per share, which was the last reported sale price of our common stock on Nasdaq on July 16, 2026. The actual number of shares of common stock issued will vary depending on the sales price under this offering. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Manner of offering </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;At the market offering&#8221; that may be made from time to time through our sales agent, Jones. See &#8220;Plan of Distribution&#8221; on page&#160;S-13 of this prospectus. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of Proceeds </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from this offering, if any, for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. See &#8220;Use of Proceeds&#8221; on page S-10 of this prospectus. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk Factors </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#8220;Risk Factors&#8221; beginning on page S-6 of this prospectus and in the documents incorporated by reference into this prospectus and any free writing prospectus that we authorize for use in connection with this offering. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq symbol </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;TVRD&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding after this offering is based on 12,492,113 shares of our common stock outstanding pro&#160;forma as of March&#160;31, 2026, consisting of 9,381,344 shares of our common stock outstanding as of March&#160;31, 2026 (actual) and after giving effect to the Prior Sales, pursuant to which we issued and sold 3,110,769 shares of our common stock in July&#160;2026 pursuant to the Sales Agreement, and excludes, as of that date: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">784,583 shares of our common stock issuable upon the exercise of outstanding options under our 2025 Equity Incentive Plan, with a weighted average exercise price of $10.43 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">713,922 shares of our common stock issuable upon the exercise of outstanding options under the Legacy Tvardi 2018 Stock Incentive Plan, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $3.21 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">8,491 shares of our common stock issuable upon the exercise of outstanding options under the Cara 2014 Equity Incentive Plan, with a weighted average exercise price of $141.14 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">680,650 shares of our common stock reserved for future issuance under the 2025 Equity Incentive Plan, as well as any increases, at the discretion of our board of directors, in the number of shares of common stock reserved for future issuance under this plan; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">199,490 shares of our common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below and discussed under the section captioned &#8220;Risk Factors&#8221; contained in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2025</a>, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus, and all other information contained in this prospectus and incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, before purchasing shares of our common stock. These risks and uncertainties are not the only ones facing us. Additional risks and uncertainties that we are unaware of, or that we currently deem immaterial, also may become important factors that affect us. If any of such risks or the risks described below or in our SEC filings occur, our business, financial condition or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose some or all of your investment.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to This Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our management will have broad discretion as to the use of the net proceeds from this offering, and we may not use the proceeds effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our management may use the net proceeds for purposes that may not improve our financial condition or market value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase in this offering.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering price per share in this offering may exceed the net tangible book value (deficit) per share of our common stock outstanding prior to this offering. Assuming that an aggregate of 3,146,027 shares of our common stock are sold at an assumed offering price of $3.08 per share pursuant to this prospectus, which was the last reported sale price of our common stock on Nasdaq on July 16, 2026, for aggregate net proceeds of approximately $9.4 million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $0.91 per share, representing the difference between our pro&#160;forma as adjusted net tangible book value per share as of March&#160;31, 2026 after giving effect to the Prior Sales and this offering at the assumed offering price. See &#8220;Dilution&#8221; in this prospectus for a more detailed illustration of the dilution you would incur if you participate in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The actual number of shares we will issue and gross proceeds resulting from those sales in this offering, at any one time or in total, is uncertain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Jones at any time throughout the term of the offering under this prospectus. The number of shares that are sold by Jones after delivering a placement notice will fluctuate based on the market price of the shares of common stock during the sales period and limits we set with Jones in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares or the gross proceeds to be raised in connection with those sales, if any, that will be ultimately issued. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The common stock offered hereby will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and so they may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:464pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may experience future dilution as a result of future equity offerings.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by any investors in this offering. Additionally, the exercise of outstanding stock options may result in further dilution of your investment. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Statements contained in this prospectus, the accompanying base prospectus, and in the documents incorporated by reference herein and therein that are not strictly historical in nature are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and within the meaning of Section&#160;21E of the Exchange Act. These forward-looking statements are subject to the &#8220;safe harbor&#8221; created by Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act and may include, but are not limited to, statements about our strategy, future financial condition, future operations, research and development, ongoing and planned clinical trials and preclinical studies, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market growth. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; the negative of these words and words or similar expressions intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to continue as a going concern; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the expectations surrounding the potential safety, efficacy, and regulatory and clinical progress of our product candidates, including TTI-101 and TTI-109, and anticipated milestones and timing therefor; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to develop and commercialize our product candidates or any potential future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential results of preclinical studies and clinical trials and future regulatory and development milestones for our product candidates or any potential future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the performance of third-party manufacturers, clinical research organizations (CROs), and other vendors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to realize the anticipated benefits of the Merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain compliance with Nasdaq listing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the size and growth of the potential markets for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance of any other future approved indications or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain additional regulatory approval of our product candidates or any future product candidates, and the labeling under any approval we may obtain; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain existing and establish additional collaborations for our product candidates or future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the continued service of our key scientific or management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish commercialization and marketing capabilities for any future approved products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory developments in the United States and foreign countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain coverage and adequate reimbursement from third-party payers and governments for any other future approved indications or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our planned use of our cash and cash equivalents and the clinical milestones we expect to fund with such proceeds; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the accuracy of our estimates regarding expenses, future revenues and capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain funding for our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain intellectual property protection for our product candidates or future product candidates and our ability to operate our business without infringing on the intellectual property rights of others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:234pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain proper and effective internal controls over financial reporting and to remediate and prevent material weaknesses in our internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of competing drugs that are or may become available; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential effects of any global health crises, geopolitical tensions and macroeconomic conditions on our business, operations, and clinical development and regulatory timelines and plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our anticipated use of proceeds from this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#8220;Risk Factors&#8221; in this prospectus and in any applicable prospectus supplement, the documents incorporated by reference herein and therein or any free writing prospectus that we authorized. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:304pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $9,689,765 from time to time under this prospectus. The amount of the net proceeds to us from this offering will depend upon the number of shares of our common stock sold and the price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Jones. Because there is no minimum offering amount required in this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from this offering, if any, for general corporate purposes, including but not limited to, clinical trial expenses, research and development expenses, general and administrative expenses and capital expenditures. We may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets, or technologies that we believe are complementary to our own, although we have no current plans, commitments, or agreements with respect to any acquisitions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the actual net proceeds from this offering (which will depend on the market price of our common stock during the sales period, any limits we may set with Jones in any applicable placement notice and the demand for our common stock), the progress of our development, the status of and results from clinical trials and collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs, including the factors described under &#8220;Risk Factors&#8221; in this prospectus and in the documents incorporated by reference herein. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share and the as adjusted net tangible book value per share of our common stock after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our net tangible book value as of March&#160;31, 2026 was approximately $14.2&#160;million, or $1.51 per share. We calculate net tangible book value per share by dividing the net tangible book value, which is total assets less total liabilities and intangible assets as of March&#160;31, 2026, by the number of outstanding shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book deficit per share of our common stock immediately after giving effect to this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our pro&#160;forma net tangible book value as of March&#160;31, 2026 was approximately $24.5 million, or $1.96 per share. We calculate pro&#160;forma net tangible book value per share by dividing the net tangible book value, which is total assets less total liabilities and intangible assets as of March&#160;31, 2026, by the number of outstanding shares of our common stock, after giving effect to the Prior Sales, pursuant to which we issued and sold 3,110,769 shares of our common stock in July&#160;2026 pursuant to the Sales Agreement, and after deducting commissions and aggregate offering expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the assumed sale by us of 3,146,027 shares of our common stock in the aggregate amount of approximately $9.7 million in this offering at an assumed offering price of $3.08 per share, which was the last reported sale price of our common stock on Nasdaq on July 16, 2026, and after deducting commissions and estimated aggregate offering expenses payable by us, our pro&#160;forma as adjusted net tangible book value as of March&#160;31, 2026 would have been approximately $34.0 million, or $2.17 per share of common stock. This represents an immediate increase in net tangible book value per share of $0.21 to our existing stockholders and an immediate dilution in net tangible book value per share of $0.91 to new investors purchasing common stock in this offering. The following table illustrates this dilution on a per share basis to new investors participating in this offering. </font>
        </div>
        <table style="width:416pt;height:137.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:346.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3.08 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:346.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Historical net tangible book value per share as of March&#160;31, 2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1.51</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:346.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma increase in historical net tangible book value per share attributable to the pro&#160;forma transactions described above </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.45 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:346.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma net tangible book value per share as of March&#160;31, 2026 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1.96 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:346.59pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Increase in pro&#160;forma as adjusted net tangible book value per share attributable </font>
                <br >
                <font style="letter-spacing:0.2pt;">to investors purchasing shares in this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.21 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:346.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma as adjusted net tangible book value per share after giving effect to this </font>
                <br >
                <font style="letter-spacing:0.2pt;">offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">2.17 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:346.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.91</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table above assumes, for illustrative purposes, that an aggregate of 3,146,027 shares of our common stock are sold at a price of $3.08 per share, the last reported sale price of our common stock on Nasdaq on July 16, 2026, for aggregate gross proceeds of approximately $9.7 million. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.08 per share shown in the table above, assuming all of our common stock in the aggregate amount of approximately $9.7 million under the Sales Agreement with Jones is sold at that price, would result in our as adjusted net tangible book value per share after this offering being $2.28 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $1.80 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $3.08 per share shown in the table above, assuming all of our common stock in the aggregate amount of approximately $9.7 million under the Sales Agreement with Jones is sold at that price, would result in our as adjusted net tangible book value per share after this offering being $1.98 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $0.10 per share, after deducting commissions and estimated aggregate offering expenses payable by us. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:270pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This information is supplied for illustrative purposes only and may differ based on the actual offering price and the actual number of shares offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The above discussion and table are based on 12,492,113 shares of our common stock outstanding pro&#160;forma as of March&#160;31, 2026, consisting of 9,381,344 shares of our common stock outstanding as of March&#160;31, 2026 (actual) and after giving effect to the Prior Sales, pursuant to which we issued and sold 3,110,769 shares of our common stock in July&#160;2026 pursuant to the Sales Agreement, and excludes, as of that date: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">784,583 shares of our common stock issuable upon the exercise of outstanding options under our 2025 Equity Incentive Plan, with a weighted average exercise price of $10.43 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">713,922 shares of our common stock issuable upon the exercise of outstanding options under the Legacy Tvardi 2018 Stock Incentive Plan, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $3.21 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">8,491 shares of our common stock issuable upon the exercise of outstanding options under the Cara 2014 Equity Incentive Plan, with a weighted average exercise price of $141.14 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">680,650 shares of our common stock reserved for future issuance under the 2025 Equity Incentive Plan, as well as any increases, at the discretion of our board of directors, in the number of shares of common stock reserved for future issuance under this plan; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">199,490 shares of our common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that outstanding options are exercised, or we issue additional options, restricted stock&#160;units, or shares of our common stock in the future, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or equity-based securities, the issuance of these securities could result in further dilution to our stockholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We previously entered into a Sales Agreement with Jones, under which we may offer and sell our shares of common stock from time to time through Jones acting as agent. We previously filed a prospectus dated May&#160;12, 2026, relating to the offer and sale of our common stock under the Sales Agreement having an aggregate offering price of up to $12,500,000, of which $11,046,550 was sold. No additional common stock will be sold under the previously filed prospectus following the date of this prospectus supplement. Pursuant to this prospectus supplement, we may offer and sell up to $9,689,765 of our shares of common stock, which amount is in addition to the common stock previously sold under the previously filed prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of our common stock, if any, under this prospectus will be made by any method permitted that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each time we wish to issue and sell our shares of common stock under the Sales Agreement, we will notify Jones of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jones, unless Jones declines to accept the terms of such notice, Jones has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jones under the Sales Agreement to sell our shares of common stock are subject to a number of conditions that we must meet. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The settlement of sales of shares between us and Jones is generally anticipated to occur on the first trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Jones may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will pay Jones a commission of up to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we previously agreed to reimburse Jones for the fees and disbursements of its counsel, payable upon execution of the Sales Agreement, in an amount not to exceed $75,000, in addition to certain ongoing disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement payable to Jones under the terms of the Sales Agreement, will be approximately $150,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Jones will provide written confirmation to us before the open on the Nasdaq Capital Market on the day following each day on which our shares of common stock are sold under the Sales Agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of our shares of common stock on our behalf, Jones will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Jones will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jones against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jones may be required to make in respect of such liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering of our shares of common stock pursuant to the Sales Agreement will terminate as permitted therein. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Sales Agreement is attached as an exhibit to the registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Jones and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jones may actively trade our securities for its own </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">account or for the accounts of customers, and, accordingly, Jones may at any time hold long or short positions in such securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available on a website maintained by Jones, and Jones may distribute the prospectus electronically. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:228pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the issuance of the common stock offered by this prospectus will be passed upon for us by Cooley LLP, Washington, D.C. JonesTrading Institutional Services LLC is being represented in connection with this offering by Paul Hastings LLP, New York, New York. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements of Tvardi Therapeutics, Inc. as of December&#160;31, 2025 and 2024, and for each of the two&#160;years in the period ended December&#160;31, 2025, incorporated by reference in this Prospectus by reference to Tvardi Therapeutics, Inc.&#8217;s <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2025</a>, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tvardi Therapeutics, Inc. The address of the SEC website is www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a website at www.tvarditherapeutics.com. Information contained in or accessible through our website does not constitute a part of this prospectus. We have included our website address as an inactive textual reference only. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:146pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, or are otherwise not incorporated into registration statements pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&#160;after the date of the filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement, and (ii)&#160;after the effectiveness of the registration statement but prior to the termination of all offerings of securities covered by this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2025, filed with the SEC on March&#160;31, 2026;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926057528/tvrd-20260331x10q.htm">our Quarterly Report on Form 10-Q for the period ended March&#160;31, 2026, filed with the SEC on May&#160;8, 2026;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the information specifically incorporated by reference into our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2025</a> from our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926047695/tvrd-20260609xdef14a.htm">Definitive Proxy Statement on Schedule&#160;14A, filed with the SEC on April&#160;23, 2026</a>; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K, filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926024676/tm268178d1_8k.htm">March&#160;6, 2026</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926072930/tm2617528d1_8k.htm">June&#160;11, 2026</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock, which is registered under Section&#160;12 of the Exchange Act, described in <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231xex4d1.htm">Exhibit&#160;4.1</a> to our Annual Report on Form 10-K, filed with the SEC on March&#160;31, 2026, including all amendments or reports filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at&#160;3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas 77478, or by telephoning us at (713) 489-8654. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="lg_tvardi-4c.jpg" alt="[MISSING IMAGE: lg_tvardi-4c.jpg]" height="54" width="135" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$200,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Preferred Stock </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Debt Securities </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:11.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may offer and sell up to $200,000,000 of any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, in one or more offerings as described in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will specify in an accompanying prospectus supplement the terms of the securities being offered. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a &#8220;smaller reporting company&#8221; under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &#8220;Summary&#8201;&#8212;&#8201;Implications of Being a Smaller Reporting Company.&#8221; </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TVRD.&#8221; On April&#160;30, 2026, the last quoted sale price for our common stock as reported on Nasdaq was $3.15. The applicable prospectus supplement will contain information as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </font>
        </div>
        <div style="margin-top:10.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; on page <a href="#sRIFA">6</a> of this prospectus and contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:22pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus is May 12, 2026.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:364pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:218.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sATP">ii</a></font><a href="#sATP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSUM"><font style="letter-spacing:0.2pt;">SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSUM">1</a></font><a href="#sSUM"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sRIFA">6</a></font><a href="#sRIFA"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sSNRF">7</a></font><a href="#sSNRF"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sUOP">9</a></font><a href="#sUOP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDOCS">10</a></font><a href="#sDOCS"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDODS">15</a></font><a href="#sDODS"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sDOW">22</a></font><a href="#sDOW"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLOOS"><font style="letter-spacing:0.2pt;">LEGAL OWNERSHIP OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLOOS">24</a></font><a href="#sLOOS"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sPOD">27</a></font><a href="#sPOD"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sLEMA">29</a></font><a href="#sLEMA"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sEXP">29</a></font><a href="#sEXP"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sWYCF">29</a></font><a href="#sWYCF"> </a>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#sIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#sIOCI">30</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell, from time to time, in one or more offerings the securities described in this prospectus up to a total dollar amount of $200,000,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of these securities and offerings. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We obtained the industry and market data in this prospectus, including the information incorporated by reference herein, from our own research as well as from industry and general publications, surveys and studies conducted by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus, any related prospectus supplement, documents incorporated by reference into&#160;this prospectus and any related free writing prospectuses. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and any related prospectus supplement, including the information incorporated by reference into this prospectus and any related prospectus supplement, include trademarks, service marks and trade names owned by us or others. All trademarks, service marks and trade names included or incorporated by reference in this prospectus, any related prospectus supplement or any related free writing prospectuses are the property of their respective owners.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sSUM">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; on page <a href="#sRIFA">6</a> of this prospectus and contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Unless the context requires otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Tvardi,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Tvardi Therapeutics, Inc. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (&#8220;STAT3&#8221;) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders&#8217; seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is our first-generation direct STAT3 inhibitor, currently in Phase&#160;1b/2 clinical development in hepatocellular carcinoma (&#8220;HCC&#8221;). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance our ability to target STAT3. We have been developing TTI-109 for several&#160;years, based on our recognition that retaining the full STAT3 inhibition mechanism of TTI-101 while enhancing delivery would broaden the potential utility of our platform across inflammatory and proliferative indications. We filed an Investigational New Drug (&#8220;IND&#8221;) application for TTI-109 in June&#160;2025 and, following FDA acceptance, initiated a Phase&#160;1 trial in healthy volunteers evaluating safety, tolerability, pharmacokinetics, and bioequivalence to TTI-101. We expect to report topline data from this trial in the second quarter of 2026, after which we intend to announce the clinical indication in which we plan to advance TTI-109. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are currently enrolling patients in the REVERT LIVER CANCER Phase&#160;1b/2 clinical trial of TTI-101 in patients with HCC. We have extended the timing of the anticipated data readout from the first half of 2026 to the second half of 2026 in order to allow the data to mature. This timing adjustment is intended to enhance the depth of insights from the program, including longitudinal and translational assessments, characterization of durability and dose optimization (including the addition of up to 15 participants in the monotherapy arm to explore modified dosages) to better inform subsequent development and regulatory strategy. The program otherwise continues to progress on schedule, and we believe the data package will strengthen decision-making and future development of our pipeline assets. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In October&#160;2025, we reported preliminary data from our REVERT IPF Phase&#160;2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis (&#8220;IPF&#8221;) and concluded that the study did not meet its goals. Subsequently, we conducted additional analyses of a subset of patients who received study drug for 12 weeks. Based on these analyses, which excluded certain patients due to dosing, pharmacokinetic, or clinical factors, treatment with TTI-101 demonstrated greater reductions in certain exploratory measures, including fibrosis and inflammatory markers, compared to placebo. These results are consistent with findings from multiple preclinical models of fibrotic disease and provide human clinical proof of concept for our STAT3 inhibition mechanism. We continue to evaluate these results to inform potential future development decisions. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our approach is rooted in our expertise around STAT3&#8217;s functional composition and its critical role in disease pathogenesis, as well as other essential biological functions. Our co-founder, David J. Tweardy, M.D., was one of the first to identify that STAT3, when activated by phosphorylation on tyrosine (Y)&#160;residue 705 (pY-STAT3), acts as a central node across multiple inflammatory, proliferative and immune pathways. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:23pt; margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Intrinsically (within proliferative cells), pY-STAT3 enhances cell proliferation and survival, while extrinsically (within the immune system), pY-STAT3 contributes to immune dysregulation. Collectively, persistent pY-STAT3 drives the development and progression of inflammatory and proliferative diseases characterized by dysregulated STAT3 signaling. By targeting pY-STAT3, our approach is designed to simultaneously modulate key pathways of the inflammatory and proliferative cascade, whereas previous approaches only targeted single pathways. Beyond its role in inflammation and proliferation, STAT3 also has an essential role in cellular respiration in the mitochondria. Dr.&#160;Tweardy made the critical discovery that blocking pY-STAT3 could inhibit STAT3&#8217;s role as a transcription factor without affecting its role in the mitochondria. We have leveraged this discovery to design our product candidates to inhibit STAT3 activation which, we believe, will lead to disease modifying activity without impairing essential biological functions. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We believe our oral small molecule STAT3 inhibitors have the potential for broad applicability across a diverse range of inflammatory and proliferative diseases driven by immune dysregulation, aberrant cytokine signaling, pathologic cellular proliferation, and maladaptive tissue remodeling. Across multiple preclinical models involving hematopoietic, gastrointestinal, dermatologic, respiratory organ specific tissue pathology, inhibition of STAT3 signaling has been associated with reductions in inflammatory burden, proliferation and improvement in disease relevant histological, molecular, and clinical parameters. Importantly, clinical data from the REVERT IPF trial, including observed reductions in IL-6 and improvements in fibrosis score, is consistent with preclinical observations, which we believe supports the translational validity of our platform. </font>
          </div>
          <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Pipeline</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our current pipeline is depicted below: </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="tb_pipeline-4c.jpg" alt="[MISSING IMAGE: tb_pipeline-4c.jpg]" height="235" width="528" >
          </div>
          <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The FDA has granted orphan drug designation for TTI-101 in both IPF and HCC as well as Fast-Track Designation for TTI-101 in HCC. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were originally incorporated in Delaware in July&#160;2004 as Cara Therapeutics, Inc. (&#8220;Cara&#8221;). On April&#160;15, 2025 (the &#8220;Closing Date&#8221;), Cara, now known as Tvardi Therapeutics, Inc., completed its previously announced merger with the Delaware corporation formerly known as Tvardi Therapeutics, Inc. (&#8220;Legacy Tvardi&#8221;) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of December&#160;17, 2024 (the &#8220;Merger Agreement&#8221;), by and among Cara, CT Convergence Merger Sub, Inc., a wholly owned subsidiary of Cara (&#8220;Merger Sub&#8221;), and Legacy Tvardi, pursuant to which Merger Sub merged with and into Legacy Tvardi, with Legacy Tvardi surviving the merger as a wholly owned subsidiary of Cara (the &#8220;Merger&#8221;). Also on April&#160;15, 2025, Cara changed its name from &#8220;Cara Therapeutics, Inc.&#8221; to &#8220;Tvardi Therapeutics, Inc.&#8221; </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Pursuant to the Merger Agreement, on the Closing Date, (i)&#160;Cara effected a 1-for-3 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;), (ii)&#160;Cara increased its authorized shares of common stock to 150,000,000, (iii)&#160;Merger Sub was merged with and into Legacy Tvardi and Legacy Tvardi became a wholly owned subsidiary of the Company, and (iv)&#160;the Company changed its name to &#8220;Tvardi Therapeutics, Inc.&#8221; As of the open of trading on April&#160;16, 2025, the common stock of the Company began trading on Nasdaq under the symbol &#8220;TVRD.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas&#160;77478, and our telephone number is (713) 489-8654. Our website address is www.tvarditherapeutics.com. Information contained on or accessible through our website is not a part of this prospectus, the accompanying prospectus or any related free writing prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> or &#8482; symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Smaller reporting companies may take advantage of certain reduced disclosure obligations. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and smaller reporting companies have reduced disclosure obligations regarding executive compensation and other matters. We may continue to be a smaller reporting company in any given year if either (i)&#160;the market value of our stock held by non-affiliates is less than $250&#160;million as measured on the last business day of our most recently completed second fiscal quarter, or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million as measured on the last business day of our most recently completed second fiscal quarter. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As a result, the information that we provide to our stockholders may be different than what you might receive from other public reporting companies in which you hold equity interests. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Securities We May Offer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We may offer shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">designation or classification; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">aggregate principal amount or aggregate offering price; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">maturity, if applicable; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">original issue discount, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">rates and times of payment of interest or dividends, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">redemption, conversion, exchange or sinking fund terms, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">ranking, if applicable; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">restrictive covenants, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">voting or other rights, if any; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">important U.S. federal income tax considerations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the names of those underwriters or agents; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">applicable fees, discounts and commissions to be paid to them; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">details regarding over-allotment options, if any; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the estimated net proceeds to us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Preferred Stock.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue shares of our preferred stock from time to time, in one or more series. Under our amended and restated certificate of incorporation, our board of directors has the authority, without further action by stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. To date, none of the 5,000,000 authorized shares of preferred stock have been issued by our board of directors. Convertible preferred stock will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the option of the holders of our preferred stock and would be at prescribed conversion rates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Debt Securities.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or preferred stock. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Warrants.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Use of Proceeds</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures, or for any other purpose we describe in the applicable prospectus supplement. See the section entitled &#8220;Use of Proceeds&#8221; in this prospectus. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Nasdaq Capital Market Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our common stock is listed on Nasdaq under the symbol &#8220;TVRD.&#8221; The applicable prospectus supplement will contain information as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the prospectus supplement.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our most recent Annual Report on Form 10-K and in our subsequent Quarterly Reports on Form 10-Q, and other reports and documents that are incorporated by reference into this prospectus and the applicable prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Statements contained in this prospectus, the applicable prospectus supplement and in the documents incorporated by reference herein and therein that are not strictly historical in nature are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and within the meaning of Section&#160;21E of the Exchange Act. These forward-looking statements are subject to the &#8220;safe harbor&#8221; created by Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act and may include, but are not limited to, statements about our strategy, future financial condition, future operations, research and development, ongoing and planned clinical trials and preclinical studies, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market growth. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; the negative of these words and words or similar expressions intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to continue as a going concern; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the expectations surrounding the potential safety, efficacy, and regulatory and clinical progress of our product candidates, including TTI-101 and TTI-109, and anticipated milestones and timing therefor; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to develop and commercialize our product candidates or any potential future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential results of preclinical studies and clinical trials and future regulatory and development milestones for our product candidates or any potential future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the performance of third-party manufacturers, clinical research organizations (CROs), and other vendors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to realize the anticipated benefits of the Merger; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain compliance with Nasdaq listing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the size and growth of the potential markets for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance of any other future approved indications or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain additional regulatory approval of our product candidates or any future product candidates, and the labeling under any approval we may obtain; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain existing and establish additional collaborations for our product candidates or future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the continued service of our key scientific or management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to establish commercialization and marketing capabilities for any future approved products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">regulatory developments in the United States and foreign countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain coverage and adequate reimbursement from third-party payers and governments for any other future approved indications or products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our planned use of our cash and cash equivalents and the clinical milestones we expect to fund with such proceeds; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the accuracy of our estimates regarding expenses, future revenues and capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain funding for our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain and maintain intellectual property protection for our product candidates or future product candidates and our ability to operate our business without infringing on the intellectual property rights of others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:234pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain proper and effective internal controls over financial reporting and to remediate and prevent material weaknesses in our internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of competing drugs that are or may become available; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential effects of any global health crises, geopolitical tensions and macroeconomic conditions on our business, operations, and clinical development and regulatory timelines and plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our anticipated use of proceeds from the sale of securities under this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#8220;Risk Factors&#8221; in any applicable prospectus supplement, the documents incorporated by reference therein or any free writing prospectus that we authorized. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:464pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures. We may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. As of the date of this prospectus, we cannot specify with certainty all of the particular uses of the net proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use of the net proceeds from the sale of securities under this prospectus as described above, we intend to invest the net proceeds in short and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws and applicable provisions of Delaware corporate law. For information on how to obtain copies of our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized Capital Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The total number of authorized shares of capital stock consists of (i)&#160;150,000,000 shares of common stock, par value $0.001 per share, and (ii)&#160;5,000,000 shares of preferred stock, par value $0.001 per share. As of December&#160;31, 2025, there were 9,381,344 shares of our common stock outstanding, and no shares of our preferred stock outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Preemptive, Redemption or Conversion Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that it may designate in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of common stock entitles the holder thereof to one vote on each matter properly submitted to a vote. Holders of shares of common stock do not have cumulative voting rights in the election of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividend Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidation Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to determine or alter for each such series, such voting powers, full or limited, or no voting powers and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof. The board of directors can also increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action by the Company&#8217;s stockholders. The board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change of control of the Company or other corporate action and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, subject to any special rights of the holders of any series of preferred stock to elect directors, our authorized number of directors shall be determined from time to time by resolution of our board of directors. Our board of directors currently has seven members. Our amended and restated certificate of incorporation provides that the directors shall be divided into three classes, with each class having a three-year term expiring on a staggered basis. </font>
        </div>
        <div style="margin-top:11.22pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent&#8217;s address is 28 Liberty Street, 53rd Floor, New York, NY 10005. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;TVRD.&#8221; </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Antitakeover Effects of Provisions of Charter Documents and Delaware Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation, our amended and restated bylaws, and certain provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) contain provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of the board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of us by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares held by stockholders. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Classification and Removal of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation provides that any director may be removed with cause by the affirmative vote of the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally at an election of directors. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Cumulative Voting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient&#160;percentage of a class of shares may be able to ensure the election of one or more directors. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Vacancies on the Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, subject to any limitations imposed by the DGCL and the rights of the holders of any series of preferred stock, any vacancies on our board of directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the board of directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum or by the sole remaining director, and not by the stockholders. </font>
        </div>
        <div style="margin-top:11.12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Action by Written Consent</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws do not provide for the right of stockholders to act by written consent without a meeting. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Stockholder Meetings</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to our amended and restated bylaws, a special meeting of the stockholders may be called only by the chairperson of the board of directors, the Chief Executive Officer, or the board of directors pursuant to a resolution adopted by the majority of the total number of authorized directors. The board of directors shall determine the time and place, if any, of such special meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Nominations and Proposals</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated bylaws provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide written notice on a timely basis and also specify requirements as to the form and content of a stockholder&#8217;s notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice of Stockholder Meeting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated bylaws provide that written notice of a meeting of the stockholders shall be given not less than 10 nor more than 60&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">If mailed, notice is given when deposited in the U.S. mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on our records. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that to the fullest extent permitted by law, we are authorized to provide indemnification of (and advancement of expenses to) our directors, officers and agents (and any other persons to which applicable law permits us to provide indemnification) through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We have entered into separate indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment of Certificate of Incorporation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding any other provisions in our amended and restated certificate of incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of stock required by law or by our amended and restated certificate of incorporation or any certificate of designation filed with respect to a series of preferred stock, the affirmative vote of the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all of the then outstanding shares of common stock entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII of our amended and restated certificate of incorporation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment of Bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the board of directors is expressly empowered to adopt, amend or repeal our amended and restated bylaws. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any adoption, amendment or repeal of our amended and restated bylaws by the board of directors shall require the approval of a majority of the authorized number of directors. Our amended and restated certificate of incorporation also provides that the stockholders shall also have power to adopt, amend or repeal our amended and restated bylaws; provided, however, that, in addition to any vote of the holders of any class or series of stock required by law or by our amended and restated certificate of incorporation, such action by stockholders shall require the affirmative vote of the holders of at least 66</font><font style=" position:relative; bottom:2.66pt;font-size:7pt;letter-spacing:0.14pt;">2</font><font style="letter-spacing:0.2pt;">&#8725;</font><font style="font-size:7pt;letter-spacing:0.14pt;">3</font><font style="letter-spacing:0.2pt;">% of the voting power of all of the then-outstanding shares of common stock entitled to vote generally in the election of directors, voting together as a single class. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Choice of Forum</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for (A)&#160;any derivative action or proceeding brought on our behalf; (B)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders; (C)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; or (D)&#160;any action asserting a claim against us governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. Notwithstanding the foregoing, these forum selection provisions do not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts of the United States have exclusive jurisdiction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Delaware Takeover Statute</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. In general, those provisions prohibit a Delaware corporation, including those whose securities are listed for trading on Nasdaq, from engaging in any business combination with any interested stockholder for a period of three&#160;years following the date that the stockholder became an interested stockholder, unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the transaction is approved by the board of directors before the date the interested stockholder attained that status; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or after such time the business combination is approved by the board of directors and authorized at a meeting of stockholders by at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;203 defines a business combination to include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any merger or consolidation involving the corporation and the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to exceptions, any transaction involving the corporation that has the effect of directly or indirectly increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation beneficially owned by the interested stockholder; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:560pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direct or indirect receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Generally, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended (the Trust Indenture Act). We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with original issue discount (&#8220;OID&#8221;) for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limit upon the aggregate principal amount that may be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the maturity date or dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the form of the debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the applicability of any guarantees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the price (expressed as a&#160;percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any restrictions on transfer, sale or assignment of the debt securities of the series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion or Exchange Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidation, Merger or Sale</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Events of Default under the Indenture</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90&#160;days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&#160;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if specified events of bankruptcy, insolvency or reorganization occur. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90&#160;days after the notice, request and offer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of Indenture; Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with the provisions described above under &#8220;Description of Debt Securities-Consolidation, Merger or Sale;&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities-General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">extending the fixed maturity of any debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the&#160;percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discharge</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">provide for payment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer or exchange of debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">replace stolen, lost or mutilated debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pay principal of and premium and interest on any debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">maintain paying agencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">hold monies for payment in trust; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">recover excess money held by the trustee; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compensate and indemnify the trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">appoint any successor trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form, Exchange and Transfer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company (&#8220;DTC&#8221;), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we elect to redeem the debt securities of any series, we will not be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&#160;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Concerning the Trustee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment and Paying Agents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two&#160;years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:584pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have filed forms of the warrant agreements as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of such securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the offering price or prices and aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency or currencies for which the warrants may be purchased; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of any rights to redeem or call the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of any rights to force the exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates on which the right to exercise the warrants will commence and expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the manner in which the warrant agreements and warrants may be modified; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of the securities issuable upon exercise of the warrants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise of Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Enforceability of Rights by Holders of Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sLOOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL OWNERSHIP OF SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders and investors in securities issued in book-entry form or in street name will be indirect holders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Book-Entry Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Street Name Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A global security may be terminated in certain situations as described under &#8220;Special Situations When a Global Security Will Be Terminated,&#8221; or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Considerations for Indirect Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it handles securities payments and notices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether it imposes fees or charges; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it would handle a request for the holders&#8217; consent, if ever required; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, the DTC will be the depositary for all securities issued in book-entry form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#8220;Special Situations When a Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Considerations for Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:14pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If securities are issued only as global securities, an investor should be aware of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Situations When a Global Security Will Be Terminated</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90&#160;days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we notify any applicable trustee that we wish to terminate that global security; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at a fixed price or prices, which may be changed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at market prices prevailing at the time of sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at prices related to such prevailing market prices; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at negotiated prices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or through the facilities of Nasdaq or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to or through a market maker other than on Nasdaq or such other securities exchanges or quotation or trading services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such &#8220;at the market offerings&#8221;, if any, may be conducted by underwriters acting as principal or agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name or names of any underwriters, dealers or agents, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price of the securities and the proceeds we will receive from the sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any options under which underwriters may purchase additional securities from us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any delayed delivery arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any public offering price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any discounts or concessions allowed or reallowed or paid to dealers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any securities exchange or market on which the securities may be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:124pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than common stock, all securities we offer will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq in accordance with Rule&#160;103 of Regulation&#160;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and the applicable prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sLEMA">&#8203;</a><a name="sEXP">&#8203;</a><a name="sWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:216pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements of Tvardi Therapeutics, Inc. as of December&#160;31, 2025 and 2024, and for each of the two&#160;years in the period ended December&#160;31, 2025, incorporated by reference in this Prospectus by reference to Tvardi Therapeutics, Inc.&#8217;s <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2025,</a> have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including Tvardi Therapeutics, Inc. The address of the SEC website is www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a website at www.tvarditherapeutics.com. Information contained in or accessible through our website does not constitute a part of this prospectus. We have included our website address as an inactive textual reference only. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="sIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:184pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, or are otherwise not incorporated into registration statements pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&#160;after the date of the filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement, and (ii)&#160;after the effectiveness of the registration statement but prior to the termination of all offerings of securities covered by this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231x10k.htm">Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2025, filed with the SEC on March&#160;31, 2026;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December&#160;31, 2025 from our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926047695/tvrd-20260609xdef14a.htm">Definitive Proxy Statement on Schedule&#160;14A, filed with the SEC on April&#160;23, 2026;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1346830/000110465926024676/tm268178d1_8k.htm">Current Report on Form 8-K, filed with the SEC on March&#160;6, 2026</a>; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock, which is registered under Section&#160;12 of the Exchange Act, described in <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/tvrd-20251231xex4d1.htm">Exhibit&#160;4.1</a> to our Annual Report on Form 10-K, filed with the SEC on March&#160;31, 2026, including all amendments or reports filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas 77478, or by telephoning us at (713) 489-8654. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.8pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:90.25pt; text-align:center; width:456pt;">
          <img src="lg_tvardi-4c.jpg" alt="[MISSING IMAGE: lg_tvardi-4c.jpg]" height="76" width="189" >
        </div>
        <div style="margin-top:59.53pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $9,689,765</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:107.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 107.166666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9.3pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:8.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 8.83333333333331pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:69.74pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">Jones</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:47.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 47.1666666666667pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:69.63pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">July 17, 2026</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:98.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 98.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.81pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.80999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_tvardi-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_tvardi-4c.jpg
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M%!04%!04%!04%/_  !$( *<!I@,!$0 "$0$#$0'_Q "^  $  @,! 0$!
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MUS;+%4VX@^DE0>?"FW$]*%I/MDJXBD"&:HZ4;*_1-A_S9'^]K(WR@J]WT?\
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M&)I_*T32@\_\2^]7[2_X*#^(JT'\_B7WJ_:;_!0?Q%*"-KY>KGD=WF7V\O\
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MB&DL2%+25QY"4)Y$E6@41Z("5 H6D@#AJ.-&%0]WLK DJ=CV#*$-CB$D,N+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tb_pipeline2-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_pipeline2-4c.jpg
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M"L.' P'B.9FP@S/$\.$P%4
M         %!M1G(>(S/ LN!<1; %<
M !0-1^UDG$\N[QPXN$!7                                 4'3,GV"
M(S(CS8EQ'L 5P                                %"29I)O S+%:2/#
MP *X                                "C*,TL+-)F1[-I;.,!53P%]P
M#Z
M                                                         #RY
MYBON/]0#Q%_J&_N 50
M     4&OYE_^C^H!7                                 6Y_P X7]G_
M (0%P                                 H/?S#']+]0"N
M                       MY7 U_:) 7
M      "C+_EU_H_60"JGS2^X!]
M
M                     !Y<\Q7W'^H!XB_U#?W *H
M                             *#7\R__ $?U *X
M               "W/\ G"_L_P#" N
M   %![^88_I?J 5P                                %O*X&O[1("X
M                                49?\NO\ 1^L@%5/FE]P#Z
M
M                                                #RYYBON/]0#Q
M%_J&_N 50                                               4&OY
ME_\ H_J 5P                                %N?\X7]G_A 7
M                           "@]_,,?TOU *X
M            "WE<#7]HD!<                                 *,O^
M77^C]9 *J?-+[@'T
M
M           'ESS%?<?Z@'B+_4-_< J@
M                   H-?S+_P#1_4 K@
M     +<_YPO[/_" N                                 %![^88_I?J
M 5P                                %O*X&O[1("X
M                   49?\ +K_1^L@%5/FE]P#Z
M
M                                   #RYYBON/]0#Q%_J&_N 50
M                                           4&OYE_P#H_J 5P
M                             %N?\X7]G_A 7
M              "@]_,,?TOU *X                                "
MWE<#7]HD!<                                 *,O\ EU_H_60"JGS2
M^X!]
M                                                           !
MY<\Q7W'^H!XB_P!0W]P"J
M        "@U_,O\ ]']0"N                                 MS_G"
M_L_\("X                                 4'OYAC^E^H!7
M                         6\K@:_M$@+@
M        !1E_RZ_T?K(!53YI?< ^@
M
M                        \N>8K[C_ % /$7^H;^X!5
M                                !0:_F7_Z/Z@%<
M                 !;G_.%_9_X0%P
M   H/?S#']+]0"N                                 MY7 U_:) 7
M                               "C+_EU_H_60"JGS2^X!]
M
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M8EW7)4*W%B4YIR.S.?6^A#BGR2:DDHSP/#9L!E+M0&( MS_G"_L_\("X
M >5F9(49<.!@/S+TTN'O*:O7-4;:M#4"H(G06')KISJD\PWN6WD-;#0E>W%Q
M.S &:27Y.[WF@A4^YKENN1/I+SZ64R"E?B<(WL#63+S;Z"-.=*58'E+@V*Q!
M/!T3<^K]0O3NHU35&W7W:'7G();Q<-Q2'(TQB8AAXFU\)),R5EX\JBXP3U>>
MZ)?58N#1Z;<=^5]V=(9K,IA52JL@CW;*68YI0;CAE@DC49EB?&!+H&!4J=58
MR9E+ELSH:S,DR(SB'FS,N'!2#,@1[ES8=/CKESY#46*WY[[ZTMMIQ\*E&1$
MLJ9<ENUIQ35'J\*H.H+%2(DEI]1$7&9-J4 R9F22,S/ BVF9\& ##L7=:DF6
M4"-7:<].,\I16Y;"WLW@R$LSQ_0 S(#'5.X*#15-IK-4B4Y3W]44N0TP:]N'
M-WBDX_H 7S3S4AI#[#B767")3;B#)25)/:1D9;#(P'L!K_5/66Q-(*3^(W=/
MR3'D+73J0P6\FRS1@1DVC81%B9$:UF22\(+1QKH]KKJ#J?WG*)+J-8G0[=JL
MF7DMEF6]^'-1VH+^Z;-K$D+,LJ5*4:.<OG; 68\'Z% Q     %![^88_I?J
M5P     !^<MPWAKQ>'>$N;36Q[WJ$)URM51BF1G9[L>(TS$4Z[D+(2LI)0W@
MDB2#)D[\H7?)TDHB[SJ]Y2YU(A+1[6]$J"IZ6"6HDI4ZS(;(C0:C(C/*HMNW
M8!X.@M*];:IJOH!=%T2#*!>-!@5&).?B?NR]I8AF\U):+;DS$HCPXED>&S $
MHB'<HU"NR[J+>TZ^;BEU5NG/0-P_4Y!N)80MM\UF2G#YI'E+';Q LNIZ96:1
M6FE/T>H1J@P@\JW8CS;Z$J\!FV:B(P8KIUUIAI;SZTM,MD:G'%F24I27"9F>
MPB 8N#==K5.3['3:W3YDP]A1X\IEUS$O\5"S,!EP&&>NZU(\LZ?(KM.:GD>4
MXKDMA+Q*\&0UYL?T ,P1D9$9'B1[2,@%G4ZQ2**RF16)\:GQU'E2[+>;809\
M.!*<-) *T.;#J$=$NGR&I41S:V^PM+K:L/ I)F1@*X#F7O=:^5[2BFTJV;,<
M3&N>NH=?=J*D)<5$AM&2"-M*R-.\<49D2C(\I)/9B9&18AI>[+>[WVE=I,ZJ
M5:^9,B,R;+U2I9SWICD0GUI2C?QWVS846924+)&;+CX,3(O@ZTT!U1=U>TTI
MMW36$1JP2W(-599Q)GVN,9$I39&9F25I4E9$9\W'#$\,026S@0   !;RN!K^
MT2 N      !P%WB;_P!6V>\7(L&R;NJ%)8J+E)A4Z$U+<C1&WYK#*<3R[$D:
MUYE'@#*%:Z-/>^I9=#F7._>DJI1*8VJ3*8@U5V0\EEHLRUDT\A!+))8F9%B?
MV >#<_=)UYK>KM#JE#N\T/75;VY6JH(0EKVR+(S$E:T((DDXA2,JC21$9&G9
MCB"3#7?='U'ON[-6[PI5U7+4*M2H-/E.QHLZ0IUEM:)S*"6E*MA&23,MG$8+
M+L.G5^A5AQUFDU.)/=8_KVXK[;ZD<7.)"C,OT@Q9$S(BQ/81<)@,*W>%I/2B
M@LUZG.3C5D*,B8PIW,9X89"7CC^@!F@&)GW3;%*D^QU2M0(4L\,(\F4RRYMX
M.:M1& R;+S,AI#[#B767")3;B#)25)/@,C+89 *4ZH0*9'5,J4IF'$1@2WY#
MB6FRQX,5+,B(!3IM6I588]JI$Z//C8Y=]$=0^WCX,S9F0"\ :G[Q&I]9TJTY
MDURVX"Y]Q2W4P:=@RM]J.MQ*EKD.I21\UM*#PS;#4:<=F(+#DJ93N]S TZ3K
MG)OF6BG&TW43I1S7-^F$\HLCQQ#;]FR&2B7D]']GB!?!U=W;=79>LFG#=?JS
M*&;@ITE=,JVY+*TZ^TA#A/(3^R2T.),RXE8X;, 26WP0   !1E_RZ_T?K(!5
M3YI?< ^@-4]X[45>F6D=>KT-\X];EH*ET5Q)Y5IF3"-!+0?I-();Q?Y +#C+
MNYZY:A4'5JWH-_7!5ZA;=S)*!NJQ*D/LE[8K+&D-D^HR(M\A*-X7[)JV@LP_
M2)2DI2:E&24I+$S/81$7&8,6-CW%;\N/(F1:M#?B1")4M]J0TMME)XX&XI*C
M));#X0%*BW7:UR*=3;M<I]74Q_7II\IF4:-N'.W2U8?I :,[UFO5<TBH=-@6
M8J$JX:PX^R](>4EYZ"AM"%)63&.!J7GYIN%EV<"L06(;#I%7DW?HSA2J^PNZ
M95LH)ZJE*0E4>HR:?L?><9VM&3F*S41%A@9D6P!#>[+:^HULP;C1J'>;%X/2
M78IP'(]5>K!1DH2[O"-3Q$:,YFG87#@!+=%9N*W[<83*N&JPZ3&69DAZ?(:B
MH,RX2)3JDD?""/5(KU#N".<R@U.)58A'@;\%]N2V1^#,TI1 .=];[-U7K>J]
M#JMGZ@1K<MIB/!1,HCU;D4YQYQN4ZIU11FR-*\Z#2@C/SL,.(%AT54:U1Z1N
M_P 6J$:!OL=U[4\VQGRX8Y<ZBQPQ+' $6=5O"T:$^Q%K=?IU-E22(XS,R8Q'
M<<)7 :$N+2:L?L 9AMQ#J$NM*);:R)2%I,C2:3+$C(RX2,!B:U=EJVT:"N.N
M4^D&Z69LJA+9BFHL<,4[U:<=I +BD5ZAW!'.70:G$JD5)Y5/P7VY+9&?$:FE
M*(!S#WF^\3<MCW90]/[(EPXR*DEAVK5MM;;\EC-*4RMA*58H:,B1BI2R,]NS
M+AB#*(=20*E3JHQ[33);,V,2C0;T9Q#R,Q8&99D&98EB#%BIE]633ZC^#S[D
MI46K8Y?8'YT=J1F\&[4LE8_H 9XC(R(R/$CVD9 ,56KIMBVB;5<5:@4A+VQD
MZA*9BDO;AS=ZI./Z ''??;U!NJ@5:RG[)NB?3:=4(4QU;E'G.L,/Y'6R2HSC
MK)*\"/8>T&4.RZ&XX[1::ZZLW'5Q6%+6H\5*4;:3,S,^$S,&*WNMYZ/:];D1
MW%-/M0)2VG4&:5H6EE9DI)EM(R/:0#\J;9URU;HM<I-PS;PK\ZE0)\=V5'?J
M,IZ.\EI9.+96E;AI42T$9&D^$@9T?HMW@K].S=$KCNJCS%,S94-$:CRV%&AP
MG:BI++;C2BP,E(2X;B3+@RX@QAQ%H!J3JG4M:;*I5P7=79=-GRTJ=A3*C*>9
M>96TXI.9MQPTJ2>&.T@92Z>[Q]FZKW)=M$EV#?\ &M*F,PB;EP9%:D4E3SV_
M6K>$TR1DOFF2<Q^# &,,9WXKLNFT[1M:3:U;GT21(J+S<AVG278BW$$QB25*
M:4DS(CVX&!#=VBD^=5=([)J53DNS:C+HT)Z5+D+4Z\ZZME)J6M:C,U*,^$S,
M"6<DWU9,.I_@LNY:5'K!*R'3W9T=$G,6S#=*62L?LP!&? 8.LWG9]N/)CW#<
M--I,A1$:6I\QB*LR/@,DNK28#(4RK4NM14SJ/.CU"$H\$R8CJ'VC,MN!+;-1
M<?A <N=Y3O$W+9E[4#3NRI<.*Q4?97JO7&W&WY+.>8MAR.1*Q;:,DM\]2R-7
M.V9<,091#J:#4:?5&/::9+9FQLQHWT9Q#R,Q<)9D&98EB#%BZK>UF4&6F!7+
MCI=,G*PRQ9LV/'=/-M+!#BTGM^X!F8\AB6RW)BNH?CNI);3S2B6A23X#2I.)
M&0"U76J,W4"I*ZC%355898*GFRD'B68L&S5FVEMX %BJ]+.15_P!=PTQ-=S;
MO\+.;'*7GQPR[G/GQQXLH#. ,#4;XLJD3RI=6N.EP*F9D10I4Z.P^9GP%NUK
M)6W[@&<0M#B$N-J);:R)25)/$C(]I&1D Q-:NRUK:R%<=<I](-TL6_Q"6S%S
M%P8IWJTX\ "XI%=H=?CG+H53B52*1X&_!?;DMD9[<,S2E$ R
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M,,U:<VTTVDD(0A%-=2E*4I(B(B(L"(@7T?H.#$     4'OYAC^E^H!7
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MKMN=XO4>O75KM?#5N4:,DG(4%V8S%4:7UJ)N-$.01H2TTE//,DFHS,C/:HU
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MZ@'B+_4-_< J@         #\[\2_/?\ _I#_ /"@R]&3[W)D7>9LC;P1*/\
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M\X;:%+21["S'P$6(]%YKBHB[ZMH[</\ 7K<+])OH CR;U[ZW_(:I_P!_I_\
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MU.(-D\<I%AMQ \6PNX6^RJP+ZC)<(Y#<UMQQO'G)0Y%,DJ,O 9H5A]P$H=W
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MDK8-EW-)=(S2E91TMX8[TL3YR=N)$97ZC@P
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MG&"RL/3([;KJ$XXY4N&68BQ/@(\ %:UK&LVR(SD2T*%!HK#QD;Y06$,J<,N
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M\"-65LB+$\-I\((MKGLVT[UAII]VT2%6H;9FIIJ<PV_NU'ABI!K(S29X<*<
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M,R+[",!7MRS;1M!E<>U:% HC+G]:FGQ6HN?#TMVE.;](#-@
M                          &1&6!\ #X1$18$6!> @'T           'E
MSS%?<?Z@'B+_ %#?W *H
M       *#7\R_P#T?U *X                                "W/^<+^
MS_P@+@                                !0>_F&/Z7Z@%<
M                       !;RN!K^T2 N
M       %&7_+K_1^L@%5/FE]P#Z
M
M                      #RYYBON/\ 4 \1?ZAO[@%4
M                               %!K^9?_H_J 5P
M                %N?\X7]G_A 7
M "@]_,,?TOU *X                                "WE<#7]HD!<
M                              *,O^77^C]9 *J?-+[@'T
M
M                                             'ESS%?<?Z@'B+_4
M-_< J@                                               H-?S+_]
M']0"N                                 MS_G"_L_\ " N
M                        %![^88_I?J 5P
M         %O*X&O[1("X                                 49?\NO]
M'ZR 54^:7W /H
M
M        /+GF*^X_U /$7^H;^X!5
M               !0:_F7_Z/Z@%<
M!;G_ #A?V?\ A 7                                 "@]_,,?TOU *
MX                                "WE<#7]HD!<
M                 *,O^77^C]9 *J?-+[@'T
M
M                                'ESS%?<?Z@'B+_4-_< J@
M                                        H-?S+_\ 1_4 K@
M                          +<_P"<+^S_ ,("X
M              4'OYAC^E^H!7                                 6
M\K@:_M$@+@                                !1E_RZ_P!'ZR 54^:7
MW /H
M                                                           /
M+GF*^X_U /$7^H;^X!5
M      !0:_F7_P"C^H!7                                 6Y_SA?V
M?^$!<                                 *#W\PQ_2_4 K@
M                       +>5P-?VB0%P
M       HR_Y=?Z/UD JI\TON ?0
M                                                       $;^H%
MD?/X/7HY1S]RTV9;S=7:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]
M>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F
M6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7
M<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_
M@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M
M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9
ME7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61
M\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<CZ@61\_@]>CE#
M<M-F6\S:=9E7<CZ@61\_@]>CE#<M-F6\S:=9E7<GES4&R";49U^#P'_Z]'@^
M\3<M+F6\S:-9E7<E.+J#9&X1_P!OPMA8?UR>(_O#<M+F6\S:-9E7<E;Z@61\
M_@]>CE%W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W
M+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG
M695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%
MD?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY
M0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,
MVG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^
MH%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7
MHY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39E
MO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W
M(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X
M/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+3
M9EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG69
M5W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?
M/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W
M+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG
M695W(^H%D?/X/7HY1-RTV9;S-IUF5=R6[6H-D>TO?]OPMN7_ -<GB+[PW+2Y
MEO-=HUF5=R7'U LCY_!Z]'*+N6FS+>:;3K,J[D?4"R/G\'KT<H;EILRWF;3K
M,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R
M/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H
M;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;
M3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4
M"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT
M<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRW
MF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D
M?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'
MKT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EIL
MRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J[D?4"R/G\'KT<H;EILRWF;3K,J
M[DMSU!LCVPO^WX7F8?UR>''[Q-RTN9;S7:-9E7<EQ]0+(^?P>O1RB[EILRWF
MFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'
MU LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z
M]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,
MMYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*N
MY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_
M!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:
M;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS
M*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LC
MY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&
MY:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY'U LCY_!Z]'*&Y:;,MYFT
MZS*NY'U LCY_!Z]'*&Y:;,MYFTZS*NY+=[4&R/:&/^WX7[7_ *Y/&7WB;EI<
MRWFNT:S*NY+CZ@61\_@]>CE#<M-F6\TVG695W(^H%D?/X/7HY1=RTV9;S-IU
MF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9
M'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4
M-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-
MIUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J
M!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ
M.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;
MS-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R
M/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#
MUZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV
M9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5=R/J!9'S^#UZ.4-RTV9;S-IUF5
M=R6\O4&R,&_^WX.Q9'_7(X"_2)N6ES+>:Q^T:R?_ .J[DN/J!9'S^#UR.47<
MM-F6\TVG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG
M695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%
MD?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY
M0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,
MVG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^
MH%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7
MHY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39E
MO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W
M(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X
M/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W(^H%D?/X/7HY0W+3
M9EO,VG695W(^H%D?/X/7HY0W+39EO,VG695W)1EZ@61[.LOQ^#B>&'[]'A+[
M1-RTN9;S-HUF5=R54Z@V0:4G^/P=I%_ZY/*&Y:7,MYFT:S*NY/OU LCY_!Z]
M'*+N6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+
M>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN
M1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P
M>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6F
MS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LR
MKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^
M?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN
M6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.
MLRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+
M(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1R
MAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9
MM.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]
M0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O
M1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+
M>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN
M1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P
M>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6F
MS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LR
MKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^
M?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN
M6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.
MLRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+
M(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1R
MAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9
MM.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]
M0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O
M1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+
M>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RAN6FS+>9M.LRKN
M1]0+(^?P>O1RAN6FS+>9M.LRKN1]0+(^?P>O1RB;EILRWF;3K,J[DO#M*U3,
MS.AT\S/:9^R,<)_T!N[/ _V6],-&X:G,OZKO=\[(VI\BI_PC'0#L\#+MZ8-P
MU.9?U7>YV1M3Y%3_ (1CH!V>!EV],&X:G,OZKO<[(VI\BI_PC'0#L\#+MZ8-
MPU.9?U7>YV1M3Y%3_A&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI@W
M#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\ ",= .SP,NWI@
MW#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT [/ R[>F#
M<-3F7]5WN=D;4^14_P"$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT [/ R[>F
M#<-3F7]5WN=D;4^14_X1CH!V>!EV],&X:G,OZKO<[(VI\BI_PC'0#L\#+MZ8
M-PU.9?U7>YV1M3Y%3_A&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_  C'0#L\#+MZ
M8-PU.9?U7>YV1M3Y%3_A&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI
M@W#4YE_5=[G9&U/D5/\ A&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NW
MI@W#4YE_5=[G9&U/D5/^$8Z =E@9=O3!N&IS+^J[W.R-J?(J?\(QT [+ R[>
MF#<-3F7]5WN=D;4^14_X1CH!V>!EV],&X:G,OZKO<[(VI\BI_P (QT [/ R[
M>F#<-3F7]5WN=D;4^14_X1CH!V>!EV],&X:G,OZKO<[(VI\BI_PC'0#L\#+M
MZ8-PU.9?U7>YV1M3Y%3_ (1CH!V>!EV],&X:G,OZKO<[(VI\BI_PC'0#L\#+
MMZ8-PU.9?U7>YV1M3Y%3_A&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,N
MWI@W#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\ ",= .SP,
MNWI@W#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT [/ R
M[>F#<-3F7]5WN=D;4^14_P"$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT [/
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MSP,NWI@W#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\ ",=
M.SP,NWI@W#4YE_5=[G9&U/D5/^$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT
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M&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI@W#4YE_5=[G9&U/D5/\
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M'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI@W#4YE_5=[G9&U/D5/^$8Z
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M&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI@W#4YE_5=[G9&U/D5/\
MA&.@'9X&7;TP;AJ<R_JN]SLC:GR*G_",= .SP,NWI@W#4YE_5=[G9&U/D5/^
M$8Z =G@9=O3!N&IS+^J[W.R-J?(J?\(QT [/ R[>F#<-3F7]5WN=D;4^14_X
M1CH!V>!EV],&X:G,OZKO<[(VI\BI_P (QT [/ R[>F#<-3F7]5WN=DK4^14_
MX1CH!V>!EV],&X:G,OZKO=F1ZWA
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0"<
M
M
M
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MB HJ][:ZK@J>B+KUK4-%7L.X(46;4[A5);95":5*B/1%)CKP6YO3,BYI<WC
MA*]";TNB'I+&JFI- 9M.U;>H=.=I=6.8W+*;3VHF*Y"VVLRFN8A"B0?./-@1
M; )1>F]X#6C45J37M(-+TS[*86MN+4ZS-;B/3=T9DHV6U+;+A+#FJ61&6!JQ
MV 43_1K72G:J/U6WJC27[8OZWSRUJW)AYG$))60W&E&E!J02CRJQ21I,RXC(
MS$PUSW</^>VO_P#OB/\ [1. EF:[WB+KN&\JG8VA5F]L9E"6;5;K<N0F)3&'
MB-230E1FDE<Y*B)1N)S&D\I*+G 47=C]X6M*ON-I=K#::[*O*HD:J.^AY,FG
M33VY4H<+$B4HR-*,%K)2BRXDK!)BC.ZRZZ1],IM(M.@49ZZM1KA_[HMZ,K(9
M-F9I)YY1)4:4F:588%MRJQ-)$9@1" 7#WCM5M,*5)G:O:;)I2)+*_P "J--E
MIEPESR2:D19)MJ=-HUD1X+S<6Q)EB9"C/7EWBJM9^G&GNI[UMM2+>NI48J\2
M)"]Y3REMI=2;>#9[PLI.^=EVDDOV@*-[O5"%'I[E5>?0FFM,JE.2L2-LF$IS
MFO$OV<NW$$:VT*U5JNL5LS[OE41-%HWM[T.BEOE/.R6&,,SR\4)).T\F!8\Y
M*@66T@0
M
M
M
M                                         ')5N?\ 7G=O^XV_]A@
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MO](,4I
M
M
M
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M5,B)Q]F9K,MI!I;(BYN=+ZS<+#@)O+^R"^CM<&(
M
M
M
M
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M<6V[REEQH;0
M
M
M
M           !&;MO&';#!-D1/U-Y.+$?'81<&=9EP)_7Y1[--IIQ9^D//BXT
M61Q:8J]<JE<D'(J4A3RL<4-\#:"\"4EL(?0X>%;AQ2V'*OOFZ:RQXVL
M                                                        C,C(
MR/ RVD9<.("=VIJ+-IJT0JVM4JG&9))]7.>:+@QQX5)+P'M\'@',U&BMN\;/
M"7LPM1-OA=Y-OLO-2&D/L+2XRZDEMN)/%*DJ+$C(R'!F)B:2Z<35[$4
M
M
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M?&:PVQ$E,S8K$R.>9B0VEUM7A2LB47D,<.ZV;9F)]'2B:Q56&*@
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M$6PA]599%EL6QY0XEUTW365L,V(
M                              #9&E]R+;?.W9:\6724Y!,_V5ESE(^X
MRYQ?;]XY&OP*Q\X_B]^EQ/'XRVJ.(Z(
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M]65LTFKI-EU+[3;R-J'$DM)_8HL2'R$Q2:.[$U>Q%
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M> \#(+G233F=I=;\JUW*^_6Z(W,?=M]B2V25T^GN*Q;B;S,I3F3TCP^PB+8
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MH4:%$7'M(R,>^8J\M:)30:<S0D,797R-IEH]Y2:?P/RGB+FJP/:E!<.)_?\
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M[*QC]^[2/DL7\<_>7=L_#'V7XU,P
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M/(2O[T?8"PZ;IU/B4FGQ*53VB8@066XL5E/FH9902$)+["21$"+D
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ME;T^AT>E*4NG068SBMBEMH(E&7@S<. SOQ;[_P 4S*6V6V^4,@-3,
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M?5:O2(4^J4I>]I<V5':>?BN&:59F7%I-39XI2>*3+@(!E0
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MG!^'K2A%\?F?+TJJHKL%-,NF$9.;VM/(<AF2=A)2ZI9YSQYIX&,9P;OE9/\
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M$S6:N[$4>Q%
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MRNVLK/23;?4AA*L^?%39;%'B1 B;
M                                                     +&L4MBM
M4R33).QN0C+FX32HMJ5%]QD1C9A8DX=T71Z,+[8NBDN>JE3I=)G/4^:C)(85
ME47$9<2B\)&6TA]7AWQ?;%T>3B76S;-)6HS8@
M           NH=2F4]N6U$62$3FCCR2-)*S-GQ%CP?>,+K(NF)GT9VW3%:>J
MT&;!]                          &RM,+:6IX[CEHP:02FX)&7G*/FJ7]
MQ%S2_3X!R-?C^'PC^+WZ7"_U2VF.(Z(
M
M (M<^FU@WI4(-5NRW8-9J%.++#?FLI>-"<V;+@K8I..W*HC(!)T(0VA+;:22
MA)$E*4E@1$6PB(B >@                            &(K-JVU<4FG3:]
M2(E2ET=[VJE/RV4/+BOXI5O&C61FA6*$GBGP$ RX
M                                               (5J/JQ8>E%,;J
M=[55$$I!FF'$0DWI<A2<,2::1BHR+$L5'@DN,R :9/OL6.7^NJLZZ4V_YWXN
M<)G=9#V9_P"OPR_T@6C=VGVI=EZHT7\>LJIHJ$-"B;DMX&W(CNF6.1YI9$I!
M^#9@?$9D"):     QM?N"BVM1Y=?N*<S3:-!1O9<V0HD-H3C@6WC,S,B2DMI
MGL+: JTBJP:[28-;ICANTVI1VID-TTJ0:V)""<;5E41&6*5$>!EB O0
M    !@(EZVM4+JFV3!J;4FYZ;'3,J,!G%:H[*U)2G>J(LJ5*S$9(,\V&W# !
MGP       06/JQ;4K5.7I"VS,*YX4 JHZ^II!0C8439X)<WF8U?O$_L8?: G
M0            ".79:$*YXY&HR8J3)&3$DBQV<.59<:?U?K]>GU-V%/!HQ<&
M+XXM+UB@U6@R#8J4=3>W!#I;6E_Y*N _UCZ+"QK<2*VRY5^'=9/BQHVM8
M                                                         E)J
M,DI(S49X$1;3,S 3ZT].9<];<ZNH5&@%@I,8^:\[]AEPI3Y?UCEZC71;X6>,
MO;A::9\;O)MQIIIAI#+*";9;22&T)+!*4I+ B(BXB'"F9F:RZ411[$4
M
M
M
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M;?*&4&EL
M
M
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M?[6()+<X(
M
M
M
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M5P*21_M$"QY.U$(0VA+;:22A)$E*4E@1$6PB(B!B]
M
M
M
M
M                                          -=:O:-VWK#284.L/R*
M;5Z0][71:W 42)<1X\N)I,RVI4:4FHMFU)&1D98@M6L9?=>O"Z&T4C436"N7
M%:25H6[1T,IB&^39D9$ZZ;SV;@_:0>W;P@5;GJUBQEZ?O6#:4QVTXR(:8-)G
M4TU)>A$UAD6V9+2HS(RYV*\5;<3Q/$$0K1[02)IC5JK=U;N"9>-^UE!,2[@J
M)&E:8Q&2MTVE3CJBS&E.8U.'YJ2+*1;2S+<((
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          /.\;],O&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33X
MR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&
M0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR
M -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0
M!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR
M-XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!
MO&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -
MXWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O
M&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -X
MWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&
M_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XW
MZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_
M33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ
M:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_3
M3XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:
M?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33
MXR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?
M&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33X
MR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&
M0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR
M -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0
M!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR
M-XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!
MO&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -
MXWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O
M&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -X
MWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&
M_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XW
MZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_
M33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ
M:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_3
M3XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:
M?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ:?&0!O&_33XR -XWZ9>,@&,[-4+
MW%OR\HM0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O
M*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA
M4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#
MLU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-
M4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!
M]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<
M6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%O
MR\H5#LU0?<6_+RA4.S5!]Q;\O*%0[-4'W%OR\H5#LU0?<6_+RA4940
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB/K<::E;IUC%;*LJRR/(0HL#_P 4!(0
M
M
M
M
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M:4&A5VY[1AVQ4JM>%#J":53*-#-+KU2<_>*=<0327%-MMI01F9H49YB(B\[
M4;5TMON7J/9\:ZIEOS+:>D.O,G3*A_7$;"S;4HN:@\IJ(R+,A)[. $3,
M
M
M
M
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M\F5T%I\-[O1ZU5-UHE38CILQW3(C-")$@S<P\&.Z2"3Y.L00
M
M
M
M
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MK!1%YQ%Q 1*(Q9G>XO2E=A*];M)M-J0U[#6;V]I;D.G'4G(ZY&C,O+P>6G'
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MN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\
M6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/
ML;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA
M\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\R
MFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_N
MU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZA
MG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&
MRX_UMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_U
MMYS[&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[
M&X8?$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?
M$_,II_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,I
MI_[M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M
M4^H9_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9
M_CALN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CAL
MN/\ 6WG/L;AA\3\RFG_NU3ZAG^.&RX_UMYS[&X8?$_,II_[M4^H9_CALN/\
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M18&!1LBVJH[7+<H];?;2R_4H,:8XR@S4A"Y#27#2DSP,R(U8$",H
M   #5NN&M]M:+6P[4J@ZW*N64A2:'0R5^]D/<!+61;4LH/:M?Z"YQD0+$)1I
MG=4N^-/[<N^<PW%F5J S->CLFHVT*>3F-*35B>!?:"(58.L-4O#6"^]-95,C
MQH%HDDX\YMQ:GGLZTI+.E192V*X@6C;X(HRY4>#%?FRW":BQFUO/NJ\U#;:3
M4I1_81%B T1:G>(7'T2DZT:D1F85/E3Y+-OTZGH6E^1'2Z;,=O!UQ69U2FW#
M4K$DY2S88$"T81O6CO+3:/VSI^C[!VJM!2F8+E0+\67$,LQ*)O8O$T\!;C-X
M$F!2&W-(M5[=UBM%NZJ ER.I#BHM2IS^&^BRVR)2FU&6Q1&2B4E1<)'Q'B1$
M3P!KZV=6J-=FI-T:<4N&^4FTV6EU*H/94-JD/+,MTTC:HTI+ \YX;=F'&96P
M00   !AKOK3UMVG7KAC,ID2*13I<]EAPS2AQ<5A;J4J,B,R(S3@9D UQ9&K5
MT7OH0>J5,M]N3=#L>:["M^*IQQ+SL20XRA"3PSF:B1CL!4\L"MW!<=G4BMW3
M2%4&X)K)N3Z0LE$J.YG41),ED2BV$1[?"")(       ##7=67K<M2NW#&:2_
M(I-.ESV6'#-*'%Q6%NI2HR(S(C-.!F0"+:(:B3=5M-:3?-1A-4^74ERDKB1U
M*6VDHTEQ@L#7MVDC$%EL($ &OJ)JU1[@U6KVE-/AO_B%MP43:G4'#2AG>.J:
MRM-IVJ5S724:SP+BV\(*V""
M                              U-2-(:A3=?Z]K*NJ,N4^L4ENE-4I+2
MB>;4A,4C6IPU93+_ %<^+]K[ 5MD$
M  &N]4=5Z9IY#3';2F;<<E.:) QP2A&TMZ\9;21B6PN%7%QF74T.@NU$U\K8
M]?9X]3JHPH^LN2KFN^XKPG'/N"<Y+=Q/=-&>5EHC_9;;+FI+[OTC[7 T^'@V
MTLBCYW$Q;L2:W2P8]#4
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M63,APC(S+FJ+$%=:4NH-5:F0JJP1I8G,-26DJPS$AY!+(CPV8X&#%=@
M
M                                #"7=<L.T+<J%Q32S-0FC4AK' W'5
M&26T$?\ C*,BQXN$>C3X,XV)%D>K5BXD8=LW3Z.%J[6ZC<=7EUNK/&_4)KAN
MO+XBXB2DN)*2(DI+B(A^B86%;AVQ;;Y0^4OOF^Z9GSECAM8/AJ2DL5&1%X3V
M$ \[YGUB?&0M)8_*/J])4E18I,E%]AXB,JAJ21DDS(C5P$9[3 J^@
M     /BE)3@:C(B,\"QV;029H^\ *^)4E18I,E%X2VD!$U?0 S(BQ/@( Q+#
M'BX<0'E+K:SP0M*C\!&1F%)2)B7H%
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MDS(UXGL(]A8<8^IVS#PM-=-\5OI,U^G@XW>77XT1;-+:PZA'R+N
M        #0.M6N5R4&ZZ=I#I)3&ZUJC5D$ZXI_G1:>PLC42W"Q21KR$;G.42
M4)P4>;$B!8A'UZ2][-<<ZP>L,8KAR[PJ8F$@H&\PQR9MSEPQV8^S@>"1:#:X
M7#=U=K>ENJ$!JDZHVUB<A+."&9K"#(E.(3B9$HLR%<P\JTJ):-F. F&_ 0
M   4I)/JC/)C&29)H43*CX"7@>4SX>,!!M'X.J=.M)4?5^HQJI=GM;JD281-
MI:]D-*-VD]TTRG$C)?[ *GP(                      #G[O/UQQJ!0[=:
M49(DN.S9!$>&),D3;9']F*UG^@?3?L>%6ZZ_Z>#C_N5_A%KFL?5N( -@Z(PH
M=0U.H\2?':E1'&Y9K8?0EUM1ICK,L4J(R/ RQ(<S]SNFW373$TGP_F]FBB)Q
MHB>*5W1JW&H-SUJA1[#M]Z/3)K\-IYQDB6M#*S22E$36!&?V#QX'[?.)AVWS
MBW_W1$_X\7HQ=9-M]UOPM\)_QZ+^V^Q^N$&KT5ZVHENWG C'*IT^F$2&UECE
M+-@E&)$O*E:5D>)'L,AJQOS=#=;=%\WV3-)B66'\-5$Q-L6W1ZPB>GT&"]I;
MJ=,G16')D%AK</NH2M;"MVO-NUJ+%.TN(>W5W71J<&(F:3/-YL"(_(Q9GT]D
M&5:UT(IWXPNAU!-)PS>VG%>)G+Z6;+P?:.A^?A_+X_**_2KS?E7TK\9I]F)S
M)RYL2RX8YL=F'AQ&]KJS,"T+NJL8IM,M^I3(9[2D,Q'5MF7A(\NW] \]^HPK
M)I==;$_=MMPK[HK%L\F)>9?CO+CR6EL26CRNLNH4VXD_ :5$1D-\3$Q6&KR\
M)9"E6W<=>0MVAT>;4FFSP<<B1W'D$?@S)+#$:L3&P\/\=T6_>6=F'??^&)E9
M2HDN!(7#GQW8DQO^LCR&U-.)^]*R(QLMNBZ*Q-88S$Q-)\)5*?3:E5Y10J1"
MD5"898^SQ6EO.8>$R01X%]XE]]MD5NF(CBMMLW32(K+W5*-6*&^F-6Z=*ILA
M98H;ELK9-1?XN<B(_P! EF)9?%;9B[[%UEULTNB860V,5U3J=.J]0C4JF,G)
MJ,QPF8L=)D1K<5P%BHR(OO,87WQ9;-UWA$,K;9NF(CSET%9VF=O6G1+H9KLN
M)5;^31I$B1 ;P?;IS"FU92+$C+>*46U9X'LYO-VG\SJ=;B8M]DV1-N'\H\?]
MT^SL8&GMPXN^4Q-]/+Z.>J01+G4Q*R)2528Q*2K:1D;B",CQX<1]/B>5WVEQ
M</SM^\-H:S6S*EZH3*5:E%<?W4*(XJ'3(QFE&8E8J-+2<"Q\)CD?MN/$::+L
M2[UGQF70UF',XTQ;'I'E_%J^9"FTZ4N%48ST.:W_ %D:2VIIU/WI61&.O;=%
MT5B:P\$Q,328I*;Z-TN-/OEBHU!!+I5OQ9-8G8X&1)CMF2,2/8?.41_H'/\
MW&^;<&8CSOF+8_B]>CMB<6L^5L59BRV;850[FU<O*,S5Y2)B_P *H"UH0AR0
M^X2LRVO!F<)*<2RDE*CP,:-3.)\[-/AS\8IXW<&>#%GQNQKXKX^$,C;&HM"O
M>N0[1O&S*.BEUATH<:13&3CR(S[FQL\V.)ECLQ2:3+AX-@U8^COP+)Q,/$NK
M;X^/C$MF'J8Q;HLOLBD_3T:TO*WNR=UU:W"=-]NGOFVR\K#,ME1$MLU8?M95
M$1_:.MIL;\W"MO\ K#PXN'^7?-OT8,>AJ
M                                  ';ND%<<N#3NAS'E&J2RR<-Y1\)
MJBJ-HC/[32E)C\^_<<+\O'NB/OS?4Z6_YX42G Y[U
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M>]K<G%2HC$%,Q\DDZZF.V3:5KR$19C).W N$$94
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M>KMUZ<UBFO2417I:*@F%*:;<=W9+;,T)=1N=N4DXH668C,B,%=D@Q
M  '+G>>S=JJ-CCD_#]G@QWZ\?\ ^O_8_TKOO_1P?W'\<?9HT?1.4 -CZ"_\
M-:B?V4W_ &98Y7[K_P!:[^'\WMT/ZT?Q2F[M.+$GW;7ITS4B# F2I\AZ1 <9
M2I;#BUF:FU'OBQ-)[. >/3ZS&MPK8C!F8B(\:^?_ (>C%T^'-]TSB1$U\GJD
MUO3?1ZF5>5;->5==[U)@XD=QE&[CL)X4F9IQ2225SU<Y2E8$18!B86HUEUL7
MV_EV6S7C*67X6GB9MN^=TJ6B-49H5A:BUB3&;GIA(CR#C2$DMIUQ#3BDDM/&
M1JP,Q?W/#G$Q\*V)I6IHK_AA8ET^-/9C-.]6=09FH-&8JM9<GPJQ+1$FP74H
M*.2'\2Q:0E)9#2>!E@?V&-VLT&!&!=-MM)MBL3Z_Q:]/JL6<6VMU8F?+V8>Y
M#H%G:QU1Z=2O;Z#3ZB<A%(9R(0M3B$N(225$:<J7%YLF&!\ WX/SQM);$74N
MFWS_ ,<&K$^.'CS,Q6(GR_QQ2:;5>\)=E:=JU"B5BE4V0YGIL-*6XL9F/C^[
M2K?$DE'AAF4HMOW#R6X>AP;/C?-MTQYSYS5ONNU6)=6WY1'IY?U7'>$@S_P6
MR:Q7XS3-V2([T6LJC&1YEM(;4:24G8>"C5AX,1A^T76_/$MLG^R)B;:LOW"V
M?C9-T?W>M$GNZF:@5JB6_-T7JB465'@(0B!37VXLA+R=IFLU$6<\,"-!J(R5
MCB6)CR:>_ LOOC4V_P!\SYS%8>C&MQ;HMG!G^VGHU9J/=]RU2@TFW[ZM]Z+=
MM)-2TUR4G<OR&,%%DR$@DJ(R-.91*/:G'C'8T>GP[;[K\*ZMEW^F/27.U&-?
M-D6XEO\ ='K]6S*E;M^VC8=OV[I;372F5..F?<E<C;I,E3RTI43:5.*+#:H\
M#(MB4X%AB8Y5F-@8V/??CSX6S2VWT>^_#Q</#MMPH\_Q3X*ME6YJ1=%+K5E:
MJT^1)HTJ,IZE56<IIR1&FI/!.5Q"C5QYDF?@,N \!CJ<;3X5UN+@3$71/C$>
M4PN#AXM\768L>'I/AYN:S2M"E-N?UC:E(7Q<Y!FD_*0^K<15B2Y<"2U-@OKC
M36#SL2&5&AQ"L#+%*BVD>!C&ZV+HI,5A8F8FL>;:^AQF<;4):C-2UT)U2UJ,
MU*4HTNXFHSQ,S^TQQOW3SPO^?LZ&A_U_;W:IHW_>%*_O,7_2H'9Q/PW?:7.P
M_.W[PWMKQJ1<5)NU=LVS+51VH[+#]1EQ"2W)DON),T$IS#-D0C# N,S^P?._
MM6CP[\+YWQ\JUI$^4.OKM1?;?\;9I]6+DU)_4[1JK5:X33(NNS'T&Q5"0E#K
MT5>4S2X:<"/%!JS;-II(^$;K;(TNKMML\+,2/+BUS=.-IYF[\5GJCUM__<_I
M#=MPGS9=Q2F+?@K(\%DTC]X_A]AD:B_0/3C?_IJK+/2R)NG^C3A_V8%]W^Z?
MC_C_ ,M:F3:3-PR(C(MJN#8.J\/A'BW+I[:<&Q(36JVH>,2/&(UVU15;)<J2
MI)Y'#0>TMA_NT_TU8$18\+5X]V//;X/C,_BN](C_ !Y\G2T^%&%'YN)X?[8]
M6KJ_6YER5RH7!4"),RI/KD.-HQ-*,VQ*$X[<$I(DE]P[&%A1A619'E$/#??-
M]TW3YRQHVL
M           !UWW<\WTY3FQP]NDY,?!@C@_3B/B/WC_L?PA]%H/TOXMM#BNB
M
M                         (S>FGUGZAQ(4&\:8FJ1:=*3/AMK<>:)N2V1
MI2O%E:#/8HRP5B7V ),
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M<P
M   '<&DE"<MW3VAP'TFB2XS[6^D^$ERE&]@?VD2B3^@?GO[AB_F8]TQY5IR?
M4Z6SX840FH\#U
M
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M&41$>2/ H
M         V+H[I\]?-SM.2FC.WJ8I+]1<,N8LR/%#!>$UF7._P 7'[!ROW'5
MQ@8?A^*[R]WMTF!^9?X^4.T.#87 /@WTP
M                        #P\\S&9<D2'$M1V4J<==69)2E""Q4HS/81$1
M;0'-D+O#:HZE3Z@YH9IZW6K3IKRXQW%69283,EUO S)I"E-88D9&19E*P,LQ
M(X 6B5:2Z^2+TNJ?IK?EN.V=J536CD+ICKF^8DLIP-2V',"VD2B5EQ41IYR5
M*(CP%%RYK+54=X=K1<J7'.E.4XZB=4WB_:"43"G<N3#+AB6'W 4;C!&EK=UL
MJM:[PMR:,.TJ.U3*'!]M:J:7%F^XK=Q5Y5(/FD7^L'P> %HW2"-1ZRZYQ-+Y
M5(MFCT9^Z-0;B,RHUO1%9%&G-D)UU>59I0:B,BP2>.57 1&9%B$ K.ONN&F[
M4:OZLZ8,Q;+=<0W-J%%G(E/0]ZHB(W$$MU/">!9C0DSV9L=@%&]9]_VI3K&7
MJ/(J"#M!$%-43/21F2XSB"6C*D\#-2\Q)2CAS'AP@C0\/7W7JY:*[?MFZ3(E
M6 69V(4J<2*I*BMF>+C323)1XD6)$AI?^+G!:-T:4ZH6[J[9T:[[=SMM+6J/
M.@O8;Z++;(C6RO#8>!*2I)EPI,CV< (U/([Q%]7Q<U4M_0:R$7/3J&\<>HW+
M4I28E/4ZDS+*SB:,Q;.:>?%1;<N&TRT9?3CO 5BJWV>E.JUK+LR_G6U/TQ*7
MBD09R$I4H]TX6)$>5*C3@I:595%F)190*)'K)K93M*6Z52H=,?N2^;A<-B@6
MW#/*Z\HC).=Q1)6:$9C))<TS4? 6!*-(B&N:KWA-8--ETZL:RZ;LTNRJ@ZB.
M]5*1,3,=AK<VEOD)6X1GAQ8IQXC,]@%'2<*9%J,./4(+R9$&6TA^-(;/,AQI
MU)+0M)\9*(R,@17
M
M                                0/4O2ZD:B0$FZ90Z]%290:BDL3(N
M'=N%^T@S_2D]I<9'T=%KK]-=];9\X>34::W%CBY(NRQ[FLJ8<.OP5LI,\&9:
M,5QG2\*'"+ _N/G%QD0^VT^JP\>*V3[OG<7!OPYI=".CU-(
M
M              #8VG^C=SWN\U*=:53+>,R-RHOI,C6C_P"PH/ UF?A\W[>(
M<K5_N.'@13\5WT]WMP-)?B>/E#KBV;9H]HT=BAT-C<0F-IF>UQQP_.<<5^TI
M6&T_T%@1$0^*Q\>_&OFZZ?%]%AX=N';\;67&AL
M                              8^NT:#<5%J-OU,EJIM5C/09B6UJ:6;
M$ELVUDE:3(TF:5'M(!BK&LFV],[4B6G;3:HM!IN^<;W[AN++?.K?<4MQ6T^<
ML]I\!;.(!S=;%5;UJ[V[=]V@C>V5I_3'*9(KC98,S)#B)+9)0O\ :(U25Y.(
MT-FK@40,O1&]3M1*!I=WQDW?<J9*Z5'H;;*TPVR>>SOQUH3@DU(+#$]NT#T;
M%_/)HQ[M7?@6_P"."4:YT)O6C:B=\&\+RM]+Z:/5*(M49,M!-/?N44]E69)*
M41<Y!X;> %GR=$W#3]:G=8:#.M^I16M(6XR4UVG.$Q[0Y(_?YC2:F5.8;6?-
M<+@^\$9^1I;:,K4>)JL^P\J\(414".^;RS92PI*T&1-'S2/!Q>TO"8(UMWL]
M0Z-;.F-1LW#V^[KQ:_#*-1FD[U]9/+)"WLB<58)X$;,5.92+CP+#4^OE&K.G
M?=(L>P*BO)59,VGP:FVE6*4K-$B:IHS+$C)MQ*4X\'-!8\W8U%ID>BT>GT:(
M@FXM.C,Q&&T[$I;8;2VDB^PB2#%S%W=&&Z=K-KM8S&+="74?:F6&S-!-&\](
M2HD&G#+S7$EL]$O "RW[IQIK:FE5OKMFSX[D>E.27)JT/.J>6;SQ)2HS4K;P
M(21?<".=;BJS&M/>LM")91%+H>FJ5R;@KS6UC?9\QLI<+8HLZ4-)V[5&X9<U
M)F#+T8.YM2J!;7>UNVZ+BCR*O.MJD1:+9]#A-F_-DU&8VRK=L)(MG]?(S'Q$
MK9B9D1CT2>Y>\))R-6[WAM(IEOZ>U]UMDI[[OXA'2I"TNH)]"6F]J5))9DE6
M<L,20K "CI^BQ:3"H]/AT%#+=#8C,MTUN+AN$Q4H(FB;R[,A(PRX<0,5\
M
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M DC,$7%"KE*N6C0;@H<E$RD5)A$J%*;\U;3J<R3P/ R/PD>TCV'M 9
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M*<BCQ,4+Q)26E-DII)D>TC2V:2P EL4$
M
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M!9=(@@
M
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MWC.&E:> W4FI9N<&W:G-P*Q+8!5T&1$DB2DL$EL(BV$1$"/H
M
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MXR2S*,L</[)L%]'4P(
M
M
M
M
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M+Z.G00
M
M
M
M                                                        $=OR
MRZ-J':-6LROH-=,JS!LK4G#.TX1DIMU&.S.VLDK3CQEM 6>F5%NRV[(I-O7I
M.C5.N4IKV(ZC#WF21'8/(PM9.D2B<W9))SAQ5B>.T!+@         !A;NCW)
M+MFJ1+/D1XES2(ZVJ9+FY]PR\X64G59$K,\A'F267:9%CL 832?3BF:56/3K
M0IR_:'6"-^ISU%@N7/>YSSZN$^<>Q)&9F2226)X )J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                    ,.=L48SQ-E>)_P#V=[IBU2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]
M%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKW
MNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]
M%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKW
MNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]
M%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKW
MNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]
M%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKW
MNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]
M%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKW
MNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV
M7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]
M>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4
M.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2
MOKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%
M2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HO
MJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2OKWNF%2AV7HOJ5]>]T
MPJ4.R]%]2OKWNF%2AV7HOJ5]>]TPJ4.R]%]2YU[W3"I1>E5(!U#\+)\O;MS[
M3NL#_JC<W6.;#+YW-PQQ$5@7-2+(9=6RY664NMJ-"TFES8I)X&7FBT&1HMTV
M_<2WFZ+.1,6P25/$@E%E)6)%YQ%PX"#,     ,:]<%&CG42>F(0=))"JB1X_
MN2=3G0:MG&6TL 'IJMTI^<S3&I25SI$8IS+)$>*HRCRDX1X88&?V@,@   "U
M<J4%J>S2W'DIGR$+=98/',I#>!*,N+9B JR9+$.,],E+)J-'0IUYQ7 EMLC4
MI1_<1 +1BN4F2[#88E(6]4&#EPT%CBXP1$><MG!@9<(!$KE(GP6:E%F-+@25
M[J.^:LJ5N9S1E3FPQ,U%@1<8#(  "D<F.F0F(IU!2EI-Q#)J+.:$F1&HD\.!
M&9;0%4  6D6J4^;+EP8LA+LN I")C2<<S:G"S)(_O(@%V L6JS2GGIT=N6WO
M:9E]O(SRDSG2:B-9G@1%@6.(#ZNKTUN3!AKDH*34TK5 01X[Y+226HTF6S D
MGB O0%)V3'86TV\ZAMQ]61E"E$1K7AC@DCX3P+'8 J@ "D<F.F0F(IU!2EI-
MQ#)J+.:$F1&HD\.!&9;0%&GU.!56G'J>^E]IIU;#BDXX$ZV>"D[2+:0"[
M                   %I!JD"I*E)@OI?5#>5%E$G'F/MX9D'CQEB NP
M%J_4H,:=%IK[Z43II.'%9/',X3)$I>'W$>("NZZVRTMYU1(:;2:UJ/@)*2Q,
M_$ I09T2I1&9\%TGXCZ26RZG'!23XRQ 7   I%)CJD*BI=0<I"2<6R2B-:4*
M/ E&GA(CPV $B3'B-&_*=0PRG C<<42$D:CP(L3PX3V *H   *,R7&@17ILQ
MPFHL="G7G58X)0DL3,\/ 0#TP^U*8:DQUDXP\A+C2RX%(66)&7WD8"H
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MMG#BDR 94   &/D5VCQ8\:6]-:*+,>3%BO$K.AQY9F1(2:<2,S-)^(!D
M     %K*J,&&_%BRGDM2)JS:BMGCBXM*<QD6'V$ N5*2A)K69)0DC-2C/ B(
MN$S,!9.UFE,^Q&Y+;RU%9-05)/,EY:BS$233B1XEQ@+X        !:.U2 Q4
M(]*=?2BH2D+<CQSQS+0WYQE]P!3:E!J\-NH4U],F$[F)MY&.5611H5ACAP&1
MD NSV;3X %K3:E!J\)JHTU],F$]FW3R,<JLBC2>&.' 9&0#XY5*>S4&:4[(2
MFHR&U/,QSQS*;1YRBXM@"T9N:@R&8$AB<VMFJ.*9IZRQP><09DI*=G$9&6T!
MD6I,=Y;K3+J''&%$AY"%$HT*,L<%$7 >!XX& J@   Q5<N2AVVRW(K<Q$1MY
M1H:S$I:E&7#@E!*4>&.W8 R;3B'FT.MGF;<22T'P8I46)<(#T  +6'4H-07)
M1"?2\N&\J-*)./,>01&:3QXRQ )E1@P%QFYCR65S'2CQB5CSW5$9DDL.,R(P
M%)FM4E_VW=RV\*:LVIRE*RI9618F2C5@18$ ]N5:G-38E/<DH3-GI6N&SQNI
M:3F4:>+86T!>     +3\2@_B7X/OT_B>X]K]FVYMQGW>?P89M@#W.G0Z9$>G
MSWDQX;"<[KSAX)27!^L!0H]:IE?@IJ5(?]IA+4I"7<JT8J2>![%DD_( OP
M 8EVYJ"Q%F3GIS:(E/?.',=/'*T^1I2:%;.'%1 ,L
M
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MUJ5FVYL"+A+C 8^W+MGO5RI4%=8C7 PQ3U3X]4C-(:R.(7D-I9-J-"N$E8I
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M4JB5RHLU6)6VY*FEMQBBKCNQ4$X9<U2LR#(\"QV_X0M8%1O:Z8,BXZ%4(T*
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M0I?%F4>&!>$16MY-WU:BR:>\]=--K3TF2S'F46,TV6[)U1)5NG&UJ5B@S_\
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M9I;4HVR)*S2:3PQ)7#L 3P10
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M3Z_.C0H-/8C2(I4Z(LU&P3F"B4:LB26I2MAY2(B+#AV@,=2:#J!2K83:33<
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MA CS4GKFEW?:3-;]B94B2ZZW @K6\M1(95G?6I9)P27 DL.,]H#9HB@
M
M                                 CS78_M:]N_9NV&Z3O<?YC=Y"PPQ
MX\F'!MR_8*)"(                        ,9)_!/QN%[3NOQW=.^PYOZW
M=;-YE^SP@,F   "$75],?Q5OM5[#^+8)_K<=YEPYN\R<6'!GXA?%$QB>R>RL
M^P;OV+(GV?<9=UN\.;DR[,N'!@(JL               #!W7V9_"O_NLW7X3
MO4?UV;)O=N7S=OA 96%[)[''_#]W[#NT>S;G#=;K*63)EV9<.# !7
M                              6U0]@]BD?BFZ_#LBO:?:,NYW>'.SYM
MF&'A 1.TOIG^(N]D_8OQ3!6;=8[W+^UDWFW+X<FP7Q1-1%
M        !CZW^#?A<CM!N/PG+_K'M67=88[,<W'CP<>/  P5F_3_ #2.QGLF
M^P_UC<X[[)CQ[SGY<?T"B6B#&4K\%WU2_!]WO?:E?B6YQR^V9$Y\W%GPRYL.
M/AV@,F     QM*_!]]4?PO)[1[4K\2RXY_:<J<<^;;YN7#BPX &2  &,I7X)
MOZC^$;KVCVE7XGNN'VG*6.?_ !L, "K_ ('O*=^,[G>>U-_AN^X?:\#R9/\
M&X< &3                                      %G5?P[\,F?B^3\+W
M*_;-YYFYRGGQPXL %K;?9_\ "&.S&Y_!^=N?9O,QQYV/'FQX<=H#+
M                      +&L?A/X;)_'-S^%9?]9]JR[G+C^UFV</!]H"/6
M=]/-](['>R>UX?O]SCO\F/\ ]DYV7'P;!42\10
L                                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tb_pipeline-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tb_pipeline-4c.jpg
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M%!04%!04%/_  !$( 6\#.0,!$0 "$0$#$0'_Q "T  $  @,! 0$!
M    ! 8#!0<" 0@) 0$!  ,! 0$              0(#! 4&!Q    8! @,%
M P<'"P(& @,!  $" P0%!A$2(1,',=*3%!5!42)AD5)3%R<(<3(CE!96&(&Q
MT4)RDN(STU15H;+!8H+"0R1$)>&D)C01 0 ! @$, 0,# P4!       !$0(#
M(5%AD1)2HF,$%"05,4'1$X$B!7&AL?#!X3)"(__:  P# 0 "$0,1 #\ _?3'
M^2W_ &2 9            8V?S5?VE?\ <8#(                      ,;
MG^8U^4_^TP&0                      8W?SFO[7_M,!D
M8GNQ']M/\X#*             Q2/\H_RI_G(!E                  &+_\
MC_T?^(#*                          ,;'^2W_9(!D           !C9_
M-5_:5_W& R                      #&Y_FM?E/_M,!D
M        &-W\YK^U_P"TP&0            !B>[$?VT_S@,H
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MF*+YT$GSK/HUA5A9RG9L^15L.2)4EQ3SSBS(]5+6LS4H_E,P)=%!
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MV*W&9A2HY2.:1NN)4I1$9Z-DDS,B4>I$0%'QWK#CU=GEO<SK:V3C,3"8V4G
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MQ?\ $$UE^7OT%'BDZ521[-RF>N&9<%<AF0RLVU.OUQ/%):CZI/\ 2J1V>SV
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M:20H_B2G70]-3 H\8IU[Q7,[!B-24U^NKGE)]&OUUJRJYZH1+-Q+#R5*-)_
MHD\Y#>X^!<0**GT__$U6W&#7N;9S6S*5F!<*JZZ.B$]NEJ?<4B-%C$:E*?E%
ML/GI3IL/M(B HLR/Q$X&G%LCR:QBVU2_B1QOV@QZQ@JC7$9,YQ#3"SCJ5H:%
MFLC)25F6G$"B1C_7_ KV?=0)"+*A725BL@=<NX+L%,BE09).=')6JU-:F1%N
M2E1^Q(%$W ^L^+Y_:JI(<&UIK5<0K.NC7D)4!4^N-1)*5%,S42VM5)]I*X_F
MZ 4=%!             !C8_R6_[) ,@           ,;/YJO[2O^XP&0
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M!S> ^\?WTGS2P\SE\1X'-X#[Q_?2?-+#S.7Q'@<W@/O']])\TL/,Y?$>!S>
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MXCP.;P'WC^^D^:6'F<OB/ YO ]?>'[Z7YI0OE\OB8^!S.%9QZ3R0
M
M
M
M
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M2TU4?#4S]H(]@
M                             .8]6Z3I^M,'+>ILAR7CE.AV/"QMS5V+
M+LIAI2TI,5'Q29.U*FV&SW$6Y1D6OQ$5RVLQVY?/IITES7S%?B>1.Y)=2<8>
ME...E7PUH>K:9Z23G,<0PU()3R#,R/82.*4@+?,QNAZ6=5\"1T_C-4M=F3]C
M5Y!C\+X(<E$."Y*:E)8(]B'6%M$E3B$ZFA9I,!MLWHZ9[':;)NO%A$?BT'F5
M2Z6O2\5+.FR5[(IE$=-QU]Y""VLM&:OTBU&2>S0.:46,V[D_IIT\S.._'PS(
M;')\A9P^:XI9QJZ$VTNJK)1DLS6E@I!O&RI1I)2229&2 &UI\?Q$ZK,:;.;9
MV+TKZ<95(=8K)+YE7KA.5\>0S"?_ *[C,=^2I;+.X]5;$;5$24@*U,A7D'&J
M6A@4,Z-AF>9HMRCP=R6J&YZ&W6K=3&D+=):HL>3)9\T\PG78UJ@DZJ-(*ZQT
M1*#53\QQ(JA>-WE3,BR++'8TLYU-'3/8WM/5JE-,FAM_8M3C9I+:X2N'O)+K
MP(                                I_4#"GLU1C*&9J87H&05V0.&IL
MW><BN6I1LEHI.TU[OSN.GN 5QSI')7B<O&O5D$N3EIY:4CDGHEL[HK;R^W?Q
M/0N7OU[>.GL!6&/T<E,3X\P[=M9,YS*SG9R#+5J5$>C%&UW_ )R3=W<SLX?F
M@*KC_P"':WJI^-2)-E3+/%[ENX]79K'"N[C3FI6=A-<D+6;FUTS^'5*E\3(B
M(B(56RBZ/2J?'L#HUVZ'EX;?R[YU\F#24E$L[#1HD[SV&GSI?%J?YO9QX"KY
M4]'I=;F4?*E7#;C;.4W&4G%)@TJ-NWJRKDL;MY\6S+F&O3CV:%V@/1=()957
MIOJ[>[]N?VYYG(/3E>I^?\KIO_.T^#F?R[?8 J3/X>+QNQBOKMJ=U5?D<?)B
MR!ZK-[(;'D3_ #I1IDQ;WPI21\I*F4EJE*>!%N28JVZ.B>0UUK+O*2]AM6D'
M);#+,6>D1''"0J]0ZBQAS4I>(EM+)S:TXUM6C37CV 538W1NV?M(>4WEVP_E
M;N3P\HNG8T9;4135?7/5S$*.A3JE)2A#A'S%J4I1[C,N/ 5:^YQ6-F'X@:RP
MA,3456-Q&Y66&]&<8KI5G!-2J5+;BTI)YUGS<EXU-FI*2)!*/70B#I&2XM(R
M*_Q2P<D-IJ,>FOVDB"MLU+?E>5<CQC)6I$DFC>6YV'JHD^X$6<      >%O,
MM&1..)09]A*41?SBQ$RE7CS<7Z]O^^G^D79G,5@\W%^O;_OI_I#9G,5@\W%^
MO;_OI_I#9G,5@\W%^O;_ +Z?Z0V9S%8/-Q?KV_[Z?Z0V9S%8/-Q?KV_[Z?Z0
MV9S%8/-Q?KV_[Z?Z0V9S%8/-Q?KV_P"^G^D-F<Q6#S<7Z]O^^G^D-F<Q6#S<
M7Z]O^^G^D-F<Q6#S<7Z]O^^G^D-F<Q6#S<7Z]O\ OI_I#9G,5@\W%^O;_OI_
MI#9G,5@\W%^O;_OI_I#9G,5@\W%^O;_OI_I#9G,5@\W%^O;_ +Z?Z0V9S%8/
M-Q?KV_[Z?Z0V9S%8/-Q?KV_[Z?Z0V9S%8/-Q?KV_[Z?Z0V9S%8/-Q?KV_P"^
MG^D-F<Q6#S<7Z]O^^G^D-F<Q6#S<7Z]O^^G^D-F<Q6#S<7Z]O^^G^D-F<Q6'
MI$AAQ6UMU"E>Y*B,_P#H),3!6&010
M     !0<YZ4P,ZOJ?)'L@N:6UHFGVJQRH?CM):.46UUPDR([Y<Q2/@W%QV\
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M(F>U%AF]A@<&+.D652RV[:ST1E>G1G'VTO-,./F9%S5MK2X24D?PGQ,@%I
M%>M,THZJPGTJE/S+^NJE7SM1"8=D2UP26MI)M(0G1:UK;4A#:3W&9=@#>L.D
M^PT^2%MDZA*R0XDT+3N+7123XD9>T@&0       ',,ZSR4Q*=I:1WE<D]DJ6
MC\_>7:A!^S3L,^W7_K[/2='$QMW_ *0\_'QYB=FUS-UYQY9N/+4XXKBI:S-2
MC_*9CV8B(^'!,O!&1]AZ^P5'T0    ?.P!]                      'U*
ME(42D&:5%Q(RX&1@+YAN?S8,EJNNGE2*YTR0E]P]7&3/@1FH^)I]^O9[/</,
MZKH[;HVK8I/^79@]1,32[X=@'@/4
M    5+,^IF$=/G:^/EMF<&1:\XZYA$>3+<>*,2#=-*(S3JM$DM.NI>T!%K.K
MW3BWIG[^OOFG*V++CUTHU-OM/,RYKB6F&W6'&TNHYBEI))K01'VZZ 47<
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M%<2:6K',<C1$M$U-=8.*;SKV\]R&VE+2TTAM))-6IF>U("]@
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M3CQ 8ZO,L0O&IK]+?UMBS6D9V+D28P^F,1$9F;QMK,D%HE7YVG88"549!0Y
MF2NAM(EHB&\J+,5!D-229D((C4TX;2E;5D1EJE7$!4<IZMXQCUQ34$*5%N;N
MRO(=!-KHDQ@Y4!4U+BB>?:(U+)*=FAI,B/B"K&69X@=]^RQ7]<>3<2]&*8QY
M[4D[S+D;]^NWXOS>SB"-)B_5C"\I@9%:Q[*/#K<8LI%59RI<F.VT@XR^63YK
M)PTI:<5KRE+,MV@"S4F04.2P2M,<M(EO6J4;93(#[<IG>G\Y.]I2DZEKQ+7@
M V(                            "L=1</1U P>]PQ<LX";J*N(<Q*.:;
M6_0]VPU)W::=FX@%29Z79A=6U-,ZCYJG(*BAF-6L"EKJMNG8<L(O&.[)63\A
M;B6E'O0VE2$[]#5KH1 K!+Z/W#=:Y!JKZ&\Q(MKFUL*NZJF[*IFHNY:I>Q^.
MIU"N9'4?Z)U#A:\2-.BN JU,3\/7H$.A7C=S%<NJBM=II;M[6-V4*3%>E.S4
M;(Q.M<@V'7W.02'-";T;5N(B,"J5/Z%SG;3'[IC(8]C95%6NH?7D%5'L62-Z
M2<I4V(PVIAJ/(W'L(R2I)MDE)D>W4Q5CB]"[>HQ&FQ&LR.)8U=<S+C2Z[(ZA
MFUK9)2I;LEN3Y;FM;)+7.4C<2S0M/ T%[!5\+H$_3,UO[(WL9$N/2Q,>L'[^
MJ8NB=;K^9Y>6T2UM&V^V3RTDG<IM2=J5)^ @*NM4%2=%20*<Y3LY4)A#"IL@
MD)=>4@M#<6324((U'Q,DI(@1L@
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M4$
M
M
M
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M=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO
M'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0
MOHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BO
MQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[
MP!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I
M4+Z*_%=[P!Z5"^BOQ7>\ >E0OHK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ >E0OH
MK\5WO 'I4+Z*_%=[P!Z5"^BOQ7>\ ^^EP_HK\5SO )@
M
M
M
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M+B2,R/:I!F1Z&1D?N/@ G
M
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MLZ#<SJA"F8=C-Y3#RIA,J4OE..)<03S9+427$JX\0)=1!
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M:FZNU%,D13YC1$Y,ORSG8NMNF+:1;\3GT3_K(HH]%R@
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MEMO_ &MNJQ_!,XMTS_UNBBPXS@V/X773:_&XZH[,PS<=2XZMW5S9M(]5F>G
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M.$THUNJ+Y"5M3K[R,?+_ ,YC1^W#CYC+/^SV?XW#G+?GR.^#Y=[0
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MD>F0\=A+@,.M*?CRF8_.E(?-9I2RE9J4E9FZ9&GB'ZK!
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ME'^4!L
M
M       '/<OS;)&<RK>GN#0H,G)),!Z\GR;=UYJ''KF'D1R(B80M:W77%[4]
MA)))J/7L!7+\.ZBY;C73&OF2SJX5A.OLB8M;3)[4D0JU<>RD;8Y<2>E*,RY;
M264Z$E.I[2T(P^Q^KN:YU]G4W'RKX9NY=8X_?(;DR3A355\*2M*V%$VE:H[B
M$F\E+B243A-D?#<8#;6O7FZH\PB5=LUC[<"5=LT2\?CV:IF11VY4HHK4MXF$
M+CHU,TNJ84K<E!D1JW_"!1WL$
M
M                                     4C,.G\B_O*[+<=O'L:RZNCO
M5Q6;##,M#]?)6AQ<=YE\C2HB6A+C:B,C2KWD9D JD?H-Z7$QI='E4MG(,9?M
MWHMS/B1+!QY-_)\U)YK;B$IYN\B-+K>TRXD>I'H"U9H?0QJLAQ4UN43TW$+)
MW\P8MY#,9]Y4F<RIB4RZCEH0M#B7'.))2I.XM/S0*H$;\/2(=?'QZ-ELYG$J
MZX:R"LJ6XT4E^:9F^>)$N2:3=E()9J))+,C[#,U&D@*NU@@
M
M
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M >HL_5/^ YW0#U%GZI_P'.Z >HL_5/\ @.=T ]19^J?\!SN@'J+/U3_@.=T
M]19^J?\  <[H!ZBS]4_X#G= /46?JG_ <[H!ZBS]4_X#G= /46?JG_ <[H!Z
MBS]4_P" YW0#U%GZI_P'.Z >HL_5/^ YW0#U%GZI_P !SN@'J+/U3_@.=T ]
M19^J?\!SN@'J+/U3_@.=T ]19^J?\!SN@'J+/U3_ (#G= /46?JG_ <[H!ZB
MS]4_X#G= /46?JG_  '.Z >HL_5/^ YW0#U%GZI_P'.Z >HL_5/^ YW0'WU%
MGZI_P7.Z E@
M
M  KU]GF$8K+9@9/DE733I".;'C6,V/$=<;W&G<E#JTF9:D9:D SX]F&)9<B0
MYBM[7WC<1242E5LMF832ED9I)9LJ5M,]#TU ;H!'F6$&N0VY826HK;SK49E;
MZTMDM]]9-MMI-1EJI:C)*4EQ,^! /$"UK+5,A=7-8FHB/NPY2HSJ'2:E1U;'
M65[#/:M"N"DGQ(^T!+  %4G=3^FM79N4MGF-)"N&E\EV!)LHK,A#GT5-K<)1
M'\F@"U)42B)23(TF6I&7$C(P'E;S+2FTNN)0IU6QHE&1&I6AJT3KVGH1GH ]
M@
M
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ME:DJX; 'ZC!
M
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MO^9YL2/SN4PHW/B/E(3VF789D"U="!
M
M                                 4#/.HMGBF1XYBE%C;N1WF2-3Y$=
ME$MB"VVU6)94X:EO\#UYQ:$0*^X=U)DW^2S\(R7'Y&+YA!AM6R:]^1'FM2*Y
MYU3"7V7XRC(]'$&A25$DRX=H"TU^3XU;,2Y-5<P9T:O,TSWHLIEY$=22,S)U
M2%&2#(B/\[0$9*V_HKEZ7&J+2)82("R;G,Q'VGUL+5KHEU+:C-!GH?!6@#Q
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M5=79=!/O2J\1L+R@Q1E$G)[EAV/';9;6P4I1142%H.4IM@R<639D1:DDC-7
M LNK=@_=-4V 8E+S+6JA7DB9%EPX##,:T4Z45*CF.-F:W$LJ7H1<$@.D1'7W
MXC#TE@XLEQM"WHRE)6II:DD:D&I!FDS2?#5)Z C,
M   "/+G0J]M#T^2U%:6XAE#CZTM)4ZZHD(01J,B-2E&24EVF8#[,FPJZ.<NP
MDM1(J5(0I]]:6FR4XHD((U*,BU4I1)+WF>@#S$L($\Y"8,IF4J(\J++)AQ+A
MM2$$1J:<VF>U9$HC-)\>) )(  \J6A!$:U$DC,DD9GIJ:CT(N/M,P&*+-A3D
MNJA2&I*675QWE,K2X2'F5;5MJVF>BDF6BDGQ(P'F'80+ GE5\IF4F,\Y%D&P
MXETFY#)Z.-+VF>U:3X*2?$O: D@
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MN9CU)=L8N M90PU:1,S/&964E"CFJ56N4:[@B-I1&TF6C@R9H22-Y$>S0S2
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M*]0/]K5^ ]_KAZ7 SW:X^Q[#$T'\2O4#_:U?@/?ZX>EP,]VN/L>PQ-!_$KU
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M)^8_Z0#S[WN3\Q_T@'GWO<GYC_I //O>Y/S'_2 >?>]R?F/^D \^][D_,?\
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MLVUD1EP,M2[1T671=;%T?$Q5JF)B9B?F$89H
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MYQHTM]NI'[-0'8>G>(MX)A-)BB'#?=KHQ%,DF9F;\QY1O27C,^.KKRW'#_M
MBC]$^C=%A>$XP>28K4-=0JUE1S;9$6*],*0:U_&4M*-YJ-*OSMWR LRKE;@W
M47$K3%<A@X\Q='33\T>L(")C#,GR^0V2),1<=;IDV:S0G5:5*3H6I:Z@)&&]
M+,QJ\RQ++;6+':4NRRZ_R"&U(2\FN>R/D''C-*VIYQI)LR<<2DBW[C[# 0BZ
M==14X<?18JEO]GSO?4/VZ*>UPK3N/6M_EMO/\X2OT.W;R]WQ\SV ,\+!NI4#
MJ$S.H*UW'(#E\].OI4>W*5C=A5.O+><6FKD<QUF<\1I2I324))S<O>9'H K\
M;I-G5/CV/,GC;[EW C6S"+?&+U-1>1')5M)FM-N/.J3'?B+0XVHT+0X:%Z_
MK4P'Z"PJ)DL'$:6'F,IF;E3$-E%O*BH)MAR422WFA*4H+37W)21]I)+L!&^
M<=ZN=%&\T>5D..K;BY'M(I++OPLRB06B3-1:[5D1::]A^W3M'N_Q_P#)_AC8
MORV_X>;U71_D_=;\_P"7Y\F]*^HL!XV7\:G+6D]-T=DY*#_(IG>7_4?36]?T
M]T5B^/\ '^7CSTV+'_F4;[.<_P#W7M/U-_N#+O,#?MUPQ[?$W9U'V<9]^Z]I
MQ[?_ *3_ ' [S W[=<';XF[.I\+IQGQ=F+VGN_\ ^)_N"]Y@;]NN#M\3=G4%
MTXSXBT+%[0B^2$_W [S W[=<';XF[.H+IQGQ<"Q>T(ODA/\ <#O,#?MUP=OB
M;LZC[-\^/MQ>T_4G^X'>8&_;K@[?$W9U/OV<Y_\ NO:?J;_<$[S W[=<';XF
M[.H^SG/_ -U[3]3?[@=Y@;]NN#M\3=G4?9SG_P"Z]I^IO]P.\P-^W7!V^)NS
MJ/LYS_\ =>T_4W^X'>8&_;K@[?$W9U'V<Y_^Z]I^IO\ <#O,#?MUP=OB;LZC
M[.<__=>T_4W^X'>8&_;K@[?$W9U'V<Y_^Z]I^IO]P.\P-^W7!V^)NSJ/LYS_
M /=>T_4W^X'>8&_;K@[?$W9U'V<Y_P#NO:?J;_<#O,#?MUP=OB;LZC[.<_\
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MF5I<)#S1[5MJVF>BDGP4D^)& S@
M    ")+JJN?(B2YT*/*E5[AO0'WVD..1W5)VFMI2B,T*,CTU3H>@"6
M
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M.H_EHL^F1!8C)A.SJYRP8>BK9T69-DUL?YJEDK=N22-"(!WT$
M
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M.X%58Q*FL+E9;1U;4(GG)DJ9#B2764(FK@M2%FADGUD9J-#:3,N' C,@*NJ
M@
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M$F+&GM\Q,6>PN++:41FE3;K2^*5H41I/V<.!F6A@C;
M
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MU>&ON@'GXWO5X:^Z >?C>]7AK[H!Y^-[U>&ON@'GXWO5X:^Z >?C?25X:^Z
MD@
M
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M3KPW$1I[ 1XC8[C[<>*U"N3T0AI$-TG6%F;J)+CS#B="T,]YNHVE\*BU+3@
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8DD1?,0@R                     /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
